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ABSTRACT
Objectives: To develop a prototype decision aid used to assist ulcerative colitis patients
when deciding between ileal pouch-anal anastomosis (IPAA) and ileostomy.
Methods: Three separate systematic reviews (quality of life studies, IPAA studies,
ileostomy studies) were conducted to populate the decision aid with outcome
probabilities. Meta-regression was used to select appropriate pooled outcomes.
Results: Of 3920 studies reviewed, 9 studies reported on quality of life, 67 on outcomes
following IPAA, and 11 following ileostomy. No difference in quality of life was found
between procedures. Among IPAA patients, pooled pouch failure rate was 5.5%, with
pouchitis being the most common complication (22%). Among ileostomy patients, the
pooled rate of ileostomy revision was 17.1%.
Conclusions: No surgical option is clearly superior and patients must weight specific
risks and benefits in deciding between procedures. This newly developed decision aid
may help patients decide which option is best for them.

KEYWORDS: Ulcerative Colitis; Decision Aid; IPAA; Restorative Pouch; Quality of
Life; Ileostomy
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CHAPTER ONE-INTRODUCTION
1.0 Overview
Some therapeutic decisions faced by patients are easy for example, use of
antibiotics to treat an infection or having surgery to remove a cancer. Few patients would
find difficulty deciding between leaving an ultimately fatal cancer to grow or removing it
with surgery. Other decisions in medicine are not as clear with the benefit of one
treatment option over another depending on the balance of differing complications and
outcomes associated with each treatment. One example is the decision between a
lumpectomy and radiation after lumpectomy (breast conserving surgery) or a mastectomy
faced by women with localized breast cancer. Both treatment options are associated with
equivalent survival1 but the implications of the treatment and its consequences for the
patient are different. Women faced with this decision must balance the increased
locoregional recurrence rate and need for adjuvant radiation associated with breast
conserving surgery versus the more invasive mastectomy entailing the removal of the
entire breast but sparing the need for radiation. This is a difficult decision as it comes at
an emotionally charged time and requires the assimilation of complex medical
information to properly weigh the risks and benefits of each option.
In an effort to enhance and support this decision making process, researchers at
McMaster University developed a decision aid to assist patients and their clinicians when
discussing these treatment options2. Their decision aid consisted of a visual aid and
written material systematically developed to present the information based on the best
available evidence to the patient during the surgical consultation. This decision aid was
subsequently tested in a randomized controlled trial involving women who faced the
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decision of breast conserving surgery or mastectomy. Use of the aid was not only
associated with improved patient knowledge about the two treatment options, but also
improved satisfaction and reduced decisional conflict3. Thus, the use of the aid not only
enhanced the decision making process but left women more satisfied with their chosen
treatment.
A similarly complex decision faces patients with ulcerative colitis. Approximately
one third of patients with ulcerative colitis will ultimately undergo a proctocolectomy
(removal of the entire colon and rectum) for the management of their disease4. Following
the removal of the colon and rectum, patients have two main reconstructive options. Both
options involve trying to overcome the loss of the reservoir function provided by the
rectum which is pivotal to maintaining control of bowel function on a day to day basis.
One is to restore intestinal continuity by fashioning a neo-rectum using the ileum and
anastomosing (joining) it to the anus, a procedure known as ileal pouchanal anastomosis (IPAA). This strategy results in a new rectum formed by the small
bowel, thus patients continue to have bowel movements via their anuses, but the
frequency of movements is increased (6-20 times per day). The other surgical option is to
bring the end of the ileum out to the skin as an ileostomy. This procedure results in
patients passing feces through the ileostomy and into an appliance. Both of these options
result in very different experiences, complications, and implications for day to day life.
This is a complex decision with lots of factors to consider for patients, and as no option
has been shown to be superior to the other5, patient preference for either procedure guides
the therapeutic decision6.
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1.1 Objective
To our knowledge, no decision aid has been developed to support and facilitate
the decision between surgical options faced by patients with ulcerative colitis. The
objective of this thesis was to develop a prototype decision aid for patients with
ulcerative colitis who are undergoing an elective proctocolectomy and have to choose
between IPAA and ileostomy. This work represents the first step in developing a decision
aid that will ultimately be refined and evaluated by patients with ulcerative colitis. In
order to appreciate the necessity for the aid, background information detailing the role of
surgery in the management of ulcerative colitis and the different surgical options will be
presented in the first chapter. This introductory chapter will also include information
about decision aids and will outline the process of decision aid formation. Subsequent
chapters will deal with the literature review and meta-analyses necessary to populate the
decision aid with information based on the best available evidence. Finally the prototype
decision aid and its plan of refinement will be presented.
1.2 Ulcerative Colitis
Ulcerative colitis is one of two major forms of inflammatory bowel disease (IBD),
the other being Crohn’s disease, and together they affect approximately 0.5% of
Canadians7. Although often lumped together, Crohn’s disease and ulcerative colitis
represent distinct clinico-pathologic entities. Ulcerative colitis is limited to the mucosa of
the bowel wall, while Crohn’s disease involves transmural inflammation. They differ in
their distribution as well, with ulcerative colitis being limited to the rectum and colon,
while Crohn’s disease can occur anywhere along the gastrointestinal tract8.
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In ulcerative colitis, chronic inflammation of the colon and rectum induces
symptoms of diarrhea, abdominal pain, bloody stools, and weight loss. In its most severe
form, the disease results in a life-threatening colonic emergency (fulminant colitis)
characterized by systemic sepsis and multi-organ failure. In addition to these effects, it
also places patients at increased risk of colon cancer. Medical treatment may temporarily
control symptoms but the only definitive treatment is surgical removal of the entire colon
and rectum. What follows is a brief look at the epidemiology, risk factors, clinical
features, diagnosis, and treatment of ulcerative colitis with specific emphasis on the role
of surgery and the surgical options.
1.2.1 Epidemiology
Ulcerative colitis is a disorder of the developed world, with the highest annual
incidences being found in Europe (24.3/100 000 person-years) and North America
(19.2/100 000 person-years) when compared to Asia and the Middle East (6.3/100 000
person-years)9. Although first described in the 19th Century, the incidence and prevalence
of ulcerative colitis have been increasing10, 11. In Canada, the estimated prevalence of
ulcerative colitis is 211.2/100 000 with an annual incidence of 12.9/100 000 personyears7. With an estimated population of 34 million in 2010, there were approximately
4000 new cases of ulcerative colitis diagnosed in that year alone12. Ulcerative colitis is
considered to have a bi-modal age distribution with most patients developing the disease
in early adulthood and a second peak of incidence in the 50-60 age range13. Mean age of
diagnosis of inflammatory bowel disease in North America ranges from 33-45 years14,
with ulcerative colitis developing 5-10 years later than Crohn’s disease15. The gender
distribution of ulcerative colitis is fairly even, however, men are more likely to develop

5
disease later in life16. In Canada, the incidence ratio between females and male is roughly
1.05, while Crohn’s disease displays a female predilection with a ratio of 1.337.
Given its chronic nature and increasing incidence, ulcerative colitis represents a
large burden on the Canadian health care system. The direct yearly cost of caring for a
patient with ulcerative colitis on the Canadian health care system is estimated at $3500
per patient. This number is much higher for those who require surgery with an estimated
yearly cost of $18,749 during the year of surgery17. Contributing to this cost is the
frequency of hospitalization which is twice that of the normal population, with an average
cost of $5000 per hospitalization12. Added to this is the indirect cost of lost productivity
as patients with ulcerative colitis missed on average 7.2 days of work in 2008,
contributing to approximately $150 million dollars in lost productivity due to
inflammatory bowel disease18. Despite its significant societal and economic impact, the
exact cause of ulcerative colitis remains elusive.
The most established theory on the etiology of inflammatory bowel disease is one
of an environmental trigger inducing an inflammatory response in a genetically
susceptible host19. According to this concept a luminal trigger, whether it be an infectious
agent (bacteria/parasite/virus) or some environmental or nutritional antigen, induces a
dysregulated, chronic, inflammatory response within the colon and rectum20. The
evidence for this theory comes largely from epidemiologic and clinic-pathologic studies
of risk factors and genetic associations.
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1.2.2 Risk Factors
Congruent with the environmental trigger-susceptible host theory of pathogenesis,
risk factors for ulcerative colitis and inflammatory bowel disease can be divided into
genetic factors and environmental factors.
Genetic Factors
Evidence of a genetic predilection for inflammatory bowel disease comes from
studies showing clustering of cases within families. Family members of patients with
ulcerative colitis have a 10 fold increase in contracting the disease when compared to age
and sex matched controls21. Further evidence is garnered from twin studies where the
monozygotic concordance rates are 18% for ulcerative colitis and 58% for Crohn’s
disease22. Families with multiply affected kindred also show a pattern of disease type
with 75% of those affected having one type of IBD only23. Although not consistent with
classical patterns of genetic inheritance (autosomal dominant, x-linked, etc) these
associations suggest a myriad of genes interplaying to produce a variable level of
susceptibility to IBD.
Currently, over 60 distinct genetic susceptibility loci have been linked with IBD24.
The most established genetic link has been made with genes encoding for the major
histocompatibility complex (MHC) on chromosome 6, known as the HLA genes25, 26.
MHC is a protein complex found on the cell membranes of all cells in the body. They
mediate the interaction between white blood cells and other cells, and are implicated in
immune function and autoimmune diseases. The most consistent association with
ulcerative colitis has been the DRB1*0103 allele. Found in less than 2% of the Caucasian
population, studies have identified the allele in up to 15.8% of patients with extensive
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colitis requiring surgery, suggesting it may also be associated with disease severity26, 27.
Other genes associated with ulcerative colitis include cellular signalling pathway genes
(JAK2, STAT3)28 and intestinal barrier function genes (ECM1,HNF4A)29, 30. The latter
group of genes encode for cell-adhesion molecules that help maintain the integrity of the
intestinal mucosa. Their association with ulcerative colitis supports the long-held belief
that compromised, “leaky”, mucosa is part of the pathogenesis of the disease31. It is
genetic attributes such as these that make a patient susceptible to the development of the
disease which is thought to result from exposure to some form of environmental trigger.
Environmental Factors
One of the strongest links to the importance of environmental factors in the
pathogenesis of ulcerative colitis comes from the consistent finding of an increasing
incidence of IBD in Western developed countries when compared to developing
countries32. When immigrants from a low incidence, developing country, travel to a
Westernized country, it is their children that develop an increased susceptibility to
inflammatory bowel disease suggesting childhood exposure to the environmental triggers
is key. It is these associations which have lead some credence to the so-called hygiene
hypothesis or “dirty” hypothesis of autoimmune diseases. According to this theory,
children that have limited exposure to bacteria from living in “sterile” modern
environments have abnormally developed immune function and are unable to
differentiate between pathogenic and non-pathogenic antigens. This results in nonpathogenic antigens, whether their own or from commensal bacteria (gut flora), inducing
chronic inflammatory reactions leading to autoimmune diseases such as IBD33. The
dysregulation of the immune system is thought to arise from dysfunction of regulator T-
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cells resulting from limited exposure to both commensal and pathogenic bacteria during
childhood and infancy34. Many features of life in a modern society are linked to reduced
bacterial exposure: improved sanitation, decline in endemic parasitism, life on concrete
with reduced exposure to soil, increase in antibiotic use, vaccination, and less crowded
living conditions32. Despite ample evidence for the hygiene hypothesis, the specific
environmental trigger(s) for IBD remain elusive. Many dietary or infectious agents have
been proposed but none have been conclusively linked16.
The specific trigger(s) and pathogenesis of IBD remain unclear, although
most of the evidence supports the environmental trigger-susceptible host theory and the
hygiene hypothesis as potential mechanisms. Given its purported autoimmune nature,
many of the therapeutic measures have been aimed at altering the immune response
within the colon and rectum.

1.2.3 Clinical Features and Diagnosis
Ulcerative colitis is characterized by inflammation affecting the mucosa and
submucosa of the rectum and colon. It progresses from the rectum proximally along the
colon, with the extent and severity of inflammation dictating the symptomatology of the
patient. The most common findings are bloody diarrhea, urgency, and tenesmus. As the
disease progresses proximally patients may complain of abdominal pain and fever. Most
patients have disease limited to the left colon and rectum (80%), while 20% will develop
inflammation throughout the colon40. Patients may also develop extra-intestinal
inflammatory manifestations involving the skin (pyoderma gangrenosum, erythema
nodosum), eye (uveitis, scleritis), joints (ankylosing spondylitis, sacroilitis), and
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hepatobiliary system (sclerosing cholangitis). These manifestations occur in
approximately 30% of patients, with the joint complications being most common41. Some
ocular and skin disorders will improve following colectomy while hepatic and articular
disorders do not, with some patients requiring a liver transplant for sclerosing
cholangitis42.
The disease course and severity is variable with some patients experiencing a
waxing and waning course with occasional disease flares and periods of remission, while
others experience severe un-remitting disease. Diagnosis is usually accomplished via
endoscopy of the rectum and colon demonstrating mucosal inflammatory changes
(redness, exudates, ulceration, loss of mucosal folds), and biopsies of the rectal/colonic
wall displaying signs of chronic inflammation (cryptitis and crypt abscesses) and
architectural distortion (crypt branching, loss of goblet cells)43. Other diagnostic
considerations include Crohn’s disease, infectious colitis, radiation colitis, and ischemic
colitis. In its most severe form, ulcerative colitis can present as fulminant toxic colitis
with associated systemic sepsis and evolving organ failure. Other urgent complications
include gastrointestinal haemorrhage, perforation, and severe dilatation of the colon
(megacolon).
One chronic consequence of long-term inflammation in the colon and rectal
mucosa is a predilection for the development of colorectal adenocarcinoma. This risk is
first materialized at approximately the 8-10 year mark following disease onset with an
associated risk of colon cancer of approximately 2%44. This risk increases with length of
disease activity to roughly 20% at 30 years45. The development of cancer is preceded by
pre-cancerous changes in the mucosa (low and high grade dysplasia), the detection of
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which usually mandates the removal of the entire colon and rectum as up to 40% of
patients with dysplasia will harbour a malignancy. This forms the rationale behind
colonoscopic screening guidelines which recommend that patients with ulcerative colitis
have a colonoscopy every 1-2 yrs with random biopsies to assess their risk of having
colon cancer starting at 8-10 years of disease activity46, 47.
1.2.4 Treatment Overview
Most cases of ulcerative colitis can be treated medically with anti-inflammatory
medications. Medical therapy is aimed at either the control of acute symptoms with
induction of remission or the maintenance of disease remission. The specific agents
chosen depend on the severity and location of disease. Mild disease limited to the rectosigmoid area (distal colon and rectum) is usually treated with topical therapies, either 5ASA compounds or steroid enemas. More severe proximal disease may require systemic
therapy, again with either 5-ASA compounds or steroids. Mild diffuse colonic disease
usually necessitates systemic therapy with 5-ASA compounds, while severe acute disease
is often treated with steroids48. Most cases will respond to steroids, but a small subset will
require emergency surgery for severe steroid-refractory disease. Once a patient recovers
on steroids, they are slowly weaned off and disease activity is monitored. Because of
severe side effects, long-term steroid therapy is not recommended to maintain remission,
thus other immunomodulators are used to treat steroid-dependent disease, where
symptoms persist or recur following steroid taper. Compounds such as 6-mercaptopurine
and azathioprine are used to blunt the body’s immune system and allow the tapering of
steroids. Other newer biologic medications, antibodies designed to target specific
molecules in the inflammatory cascade, are also used to treat steroid refractory disease.
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Infliximab, a monoclonal antibody active against tumor necrosis factor alpha (TNF), is
used to treat steroid dependent or resistant disease, to both induce and maintain
remission49. Most patients can be successfully managed with medical treatment alone but
up to 25% will ultimately require surgery for the treatment of their disease4, 50.
1.2.5 Role of Surgery
One of the major differences between Crohn’s disease and ulcerative colitis is the
ability to cure ulcerative colitis with removal of the rectum and colon (proctocolectomy).
The indications for surgery can be grouped by urgency with both elective and emergent
conditions requiring surgery. The most common elective indication for surgery is failure
of medical management4, 51. These are patients who have ongoing symptoms despite
medical management, or who are unable to tolerate the withdrawal of steroids. The use
of newer agents, such as infliximab, has not reduced the need for colectomy52. Another
elective indication for surgery is increased risk of cancer. Total proctocolectomy is
recommended for patients with ulcerative colitis who have a current colon cancer,
dysplasia associated lesion or mass (DALM), or high grade dysplasia. Both DALM and
high-grade dysplasia are associated with high risks of concurrent adenocarcinoma with up
to 40% rates of concurrent cancer identified when the specimens are reviewed
pathologically53. The recommendations are less clear for patients with low grade
dysplasia, as the risk of concurrent cancer is less well defined with risks of developing
future high grade dysplasia or cancer ranging from 18-54%54-56. Most practitioners would
recommend surgery in a good risk patient but obviously the decision is highly
individualized based on patient factors51, 57.
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Severe acute colitis affects 10-15% of patients with ulcerative colitis and is
characterized by frequent bloody bowel movements, fever, tachycardia and anemia. Such
patients may progress to develop fulmitant colitis characterized by systemic sepsis and
evolving organ failure, or develop megacolon defined as transverse colonic dilatation
greater than 6 cm. Both of which are generally considered indications for emergent
surgery4, 51. Approximately 20-30% of patients with severe acute colitis will require
surgery58. The surgical options considered in the emergent setting differ from the elective
situation. The sole priority during emergent surgery is to remove the source of systemic
toxicity, the colon, thus subtotal colectomy with ileostomy is the procedure of choice51, 59.
This entails leaving the rectum in-situ as removal of the rectum entails a more involved
procedure with increased risks of morbidity and potentially mortality, and disease of the
rectum alone is rarely life-threatening. Reconstructive options such as an ileal pouch-anal
anastomosis are not appropriate in the acute setting given the increased complexity of the
surgery. Removal of the rectum with IPAA can be considered electively months later
once the patient has recovered from their acute illness. Patients who develop colonic
perforation are also treated with a subtotal colectomy and ileostomy, although they carry
a much higher mortality60, 61. Patients with acute colitis who fail to respond to medical
management within 72-96 hours should also be offered colectomy62. Following a subtotal
colectomy and ileostomy, these patients have the option to choose from either keeping
their ileostomy or undergoing a restorative pouch procedure. Electively, patients have
options to choose from, these will be described in the following section.
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1.2.6 Elective Surgical Options
Patients who have elective surgery for ulcerative colitis, whether it is for
intractability or cancer risk, have options to choose from. The main options are either a
total proctocolectomy (removal of entire colon and rectum) and ileostomy, or total
proctocolectomy with ileal pouch-anal anastomosis (IPAA). Other options such as the
continent ileostomy (Koch pouch) and ileoproctostomy have very limited roles in the
modern surgical management of ulcerative colitis and have largely fallen out of favour.
The Koch pouch has been associated with a high rate of revision and re-operation (up to
50%), while the ileoproctostomy leaves the rectum insitu which is at risk of malignancy4.
Total proctocolectomy and ileostomy
This procedure involves the removal of the entire colon and rectum, and the
connection of the end of the small bowel to the skin (ileostomy or stoma). Digested
material passes through the small bowel and is emptied into a bag that is worn on the skin
with the aid of an appliance. It is the conventional, benchmark procedure for ulcerative
colitis to which all others are compared. It is well established as being safe and allows
patients to continuing living active lives63. It is considered the first line procedure in those
who choose to undergo it rather than IPAA, or those who are not candidates for IPAA
(impaired fecal continence, peri-anal disease, multiple comorbidites)51. It has the benefit
of only requiring one procedure whereas restorative proctocolectomy (IPAA) is often
done as a staged procedure. Complications following this procedure include stoma related
complications (prolapse, retraction, peri-stomal hernia), small bowel obstruction,
unhealed perineal wound, and sexual and bladder dysfunction64-67. The most distressing
feature of this procedure for patients is the creation of the ileostomy. This necessitates
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emptying the bag of small bowel feces roughly 6-10 times per day. Although the idea of a
stoma seems difficult to accept for patients, most patients who undergo the procedure are
satisfied with their result6, 68, 69. A systematic review of outcomes following this
procedure will be presented later in the thesis, while a separate chapter will be devoted to
a quality of life comparison between this procedure and IPAA.
Ileal pouch-anal anastomosis (IPAA)
During this procedure, the small bowel (ileum) is used to construct a pouch that
functions as a neo-rectum allowing patients to defecate via their anus. The only true
advantage it has over the traditional therapy is the avoidance of an ileostomy and the
restoration of anatomic defecation. This advantage does come at a cost of a more lengthy
procedure with its own set of complications and risks. Most of these complications are
related to the creation and malfunction of the ileal pouch, which does not function
perfectly as a new rectum. In this option patients typically have a staged surgery where
the colon and rectum are removed, the pouch created and the fecal stream diverted
proximal to the pouch with a loop ileostomy. This ileosotmy is later closed during a
second procedure. Chapter three will summarize a detailed systematic review of trials
comparing the quality of life between ileostomy and IPAA, while Chapter four will
review the outcomes following IPAA.

1.3 Decision Aids
Most clinical decisions faced by patients and surgeons involve the balance of risks
and benefits. The uncertainty of potentially poor outcomes at the patient level makes this
process difficult and distressing to patients and surgeons alike. Traditional models of
clinical decision making, namely paternalistic ones where surgeons simply determined
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what they felt was the best option for the patient and proceeded with such have been
abandoned in favour of a shared-decision making process77. At the conceptual level,
shared-decision making has four necessary characteristics: 1) Both the physician and the
patient are involved in the treatment decision making process. 2) Both the physician and
the patient share information with each other. 3) Both the physician and the patient take
steps to participate in the decision making process by expressing treatment preferences.
4) A treatment decision is made and both the physician and patient agree on the treatment
to implement78. Within this framework are three well-defined stages: information
exchange, deliberation, and deciding on a treatment. The utility of decision aids are built
into this framework by facilitating the information exchange between the patient and the
surgeon; and by clarifying a patient’s preferences during the deliberative stage of
decision making77.
But do patients want to be involved in their treatment decisions? Two studies have
addressed this issue in patients with IBD. In a survey of over 1000 patients with either
Crohn’s disease or ulcerative colitis, 81% of patients indicated they wanted to be actively
involved in their treatment decisions79. In a second study of over 1000 patients with IBD,
80% of patients indicated they wanted more information about treatment options when
discussing treatments with their physicians80. With an obvious desire for more
involvement, and with IBD patients being often young and knowledgeable about their
condition, this is a population ideally suited for the use of decision aids.
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1.3.1 Objectives of a Decision Aid
The main goal of decision aids is to facilitate informed, preference-sensitive
decision making81. Not all clinical decisions are necessarily “preference-sensitive” and
thus some clinical decisions are better suited to the use of decision aids. Wennberg has
divided clinical decisions into those that are “effective”, meaning decisions where the
benefit is clear to both the patient and the physician (antibiotics for an infection) and
those that are “preference-sensitive”, where the optimal strategy is unclear and depends
on the preferences and values of an individual patient82. The decision between a
restorative pouch procedure or an ileostomy is clearly a “preference-sensitive” decision.
Both options result in a similar control of disease, but one avoids the need for an
ileostomy at a cost of different complication profile and the need for more procedures.
The process of shared-decision making should respect a patient’s individual values,
personal resources, and capacity for self determination83. It is built upon a therapeutic
alliance where responsibility for the decision and outcome are shared by the care team84.
Patients can often find complex medical decision making troubling, a phenomena known
as decisional conflict85. Uncertainty around the decision and its potential outcomes results
not only from the inherent complexity of balancing various risks and benefits, but also
from modifiable factors such as lack of information, lack of understanding, unclear
values, and inadequate support during the decision making process. O’Connor has
developed nine objectives that have been adopted as pillars for the development and
design of decision aids: 1) Improve knowledge of the clinical problem, options,
outcomes, and variation in patient or practitioner opinions and practices. 2) Create
realistic expectations of outcomes, consistent with available evidence. 3) Clarify personal
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values for outcomes and promote congruency between patient values and choices. 4)
Reduce patients’ and practitioners’ decisional conflict (uncertainty) about the course of
action to take. 5) Promote implementation of choices. 6) Improve patients’ and
practitioners’ satisfaction with decision making. 7) Promote patients’ persistence with
choice. 8) Reduce patients’ distress from the consequences of decisions. 9) Improve
patients’ health-related quality of life and promote informed use of resources by patients
and practitioners86. It is along these objectives that decision aids should be designed and
evaluated.
1.3.2 Design of a Decision Aid
To develop a decision aid, the first step is the consolidation of the best evidence
for the individual treatment options explored. In order to gather the necessary data, a
systematic review of outcomes following both IPAA and ileostomy will be undertaken in
order to populate the prototype decision aid with data. This will form the rough prototype
that will be further refined by input through surgeons, ostomy wound care specialists, and
patients themselves. A Delphi conference of experts in the field of decisional support, the
International Patient Decision Aid Standards Collaboration, established 12 quality criteria
for the development of decision aids which were used as a guide to the development of
our aid: 1) systematic development process; 2) providing information about options; 3)
presenting probabilities; 4) clarifying and expressing values; 5) using patient stories; 6)
guiding or coaching in deliberation and communication; 7) disclosing conflict of interest;
8) delivering patient decision aids on the internet; 9) balancing the presentation of
choices; 10) using plain language; 11) basing information on up to date scientific
evidence; and 12) establishing effectiveness. The only criterion that we do not consider
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significant is the use of patient stories. Some literature has shown the inclusion of patient
stories can bias patients’ preferences and potentially unduly influencing their decision87.
Thus patient stories were not included in the development of the aid.
Following the collection of outcome probabilities from the literature, the
prototype aid will further be refined by three sets of focus groups, one with colorectal
surgeons, one with enterostomal therapists, and one with patients. The resulting refined
prototype will then be tested for validity and reliability on healthy volunteers, as it is
clinically inappropriate and potentially unethical to manipulate information concerning
therapy and outcomes to patients at the decision point88, 89. Finally with a valid and
reliable decision aid, it will be tested on patients for effectiveness. Various outcomes
have been proposed for the evaluation of decision aids. Demonstrating an increase in
knowledge about the treatment options by the use of a decision aid is an obvious first step
in evaluating the effectiveness of the aid, and is fairly straightforward with the use of pre
and post questionnaires. Moving beyond a demonstration of improved knowledge
acquisition, the purpose of the decision aid is to enhance the overall decision making
process and ultimately result in an improved quality of life for the patient. Various scales
have been developed to test the conceptual aspects of an enhanced decision making
process. One of the most studies is the Decisional Conflict Scale, developed by
O’Connor. This scale operationalizes the degree of uncertainty patients experience when
facing a treatment decision. This scale consists of 16 questions with Likert scale
responses that explore three domains: decisional uncertainty, factors contributing to
uncertainty, and perceived effective decision making. This scale has been validated85 and
used in the evaluation of different decision aids3. Other metrics that have been used to
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evaluate decision aids include measures of anxiety, satisfaction with the decision2, and
preference for independent decision making90. Ultimately the goal of the decision aid is
to improve a patient’s quality of life. This has been difficult to demonstrate reliably as
current generic and even disease-specific measures of health-related quality of life may
not be sensitive enough to capture the specific aspects of decisional uncertainty. Thus
most of the literature has typically utilized a mixture of patient knowledge, decisional
conflict, and satisfaction assessments in combination with the degree of patient
participation as ways to establish the effectiveness of these aids. In a systematic review of
over 30 trials examining the effectiveness of decision aids, the use of these aids was
found to improve patients knowledge, improve the proportion of patients with realistic
perceptions of the risks and benefits of the therapies, lower decisional conflict, reduce the
proportion of patients who are passive decision makers, reduce the proportion of patients
who remain undecided after counselling, and improve the agreement between a patient’s
values and the option chosen91. It is along these metrics that our aid will ultimately be
evaluated by.
1.4 Overview of the Thesis
This thesis is designed in the integrated article style, following the introductory
chapter, chapter two will describe the methodology behind the systematic literature
review and quality assessment necessary for the creation of the prototype decision aid.
Chapter three will present the results of the systematic review of quality of life literature
comparing ileostomy and IPAA treatment options. Chapter four will summarizes the
results of the systematic review and meta-analysis of outcomes following the IPAA
option, while chapter five will discuss the results of the outcomes following the ileostomy
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option. Finally, chapter six will outline the methodology behind the refinement and
validation of the prototype decision aid.
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CHAPTER TWO - SEARCH STRATEGY AND STUDY INCLUSION FOR
SUBSEQUENT SYSTEMATIC REVIEWS
2.0 Introduction
In order to populate our decision aid with information, a systematic review was
undertaken of the literature reporting on surgical outcomes following proctocolectomy
with either an ileal pouch-anal anastomosis (IPAA) or an ileostomy. Concurrent with this
systematic review, studies reporting on the differences in quality of life between the two
approaches were also reviewed. Rather than conduct three different searches of the same
literature, we combined the three searches into one broad literature search. This allowed
the inclusion of a large number of studies in our index search, and eliminated the
redundancy of having to undertake three separate searches of the same databases for
studies reporting on outcomes following proctocolectomy. The implications of this broad
approach resulted in a very large number of abstracts reviewed, allowing the abstract
reviewers the ability to apply apriori study inclusion criteria over a wide range of
screened articles. This chapter serves as part of the methods for the subsequent three
chapters which report on the specific results of the systematic reviews of three groups of
articles: studies comparing quality of life between IPAA and ileostomy, studies reporting
on outcomes following IPAA, and studies reporting on outcomes following ileostomy.

2.1 Search Strategy
Studies were identified by searching the following databases in conjunction with
the help of a professional librarian experienced in systematic reviews (Erin Boyce):
-

Medline (1978-2009)
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-

Embase (1978-2009)

-

CINAHL

-

Cochrane Database of Systematic Reviews

The search strategy used was a combination of MESH (medical subject heading)
terms and key words. For example, when searching Medline, the following strategy was
used:
MESH terms
Disease identifiers:
ulcerative colitis, inflammatory bowel disease,

Procedure identifiers:
restorative proctocolectomy, ileostomy,

Key words:

Disease identifiers:
Inflammatory bowel disease, ulcerative colitis, IBD, colitis

Procedure identifiers:
Proctocolectom$, colectom$, ileal pouch-anal anastomosis, IPAA, ostom$,

The disease identifiers were combined with the procedure identifiers and the
“explode” function was used to further broaden our search. No limits were placed on
language at this stage of our search. A similar strategy was employed when searching the
other databases mentioned above with modifications taking into account the differences
in MESH terms and key words inherent to each specific database. The search was limited
to papers published in 1978 or later as this was the year when Parks published the first
report on IPAA1. The search was last updated on January 30, 2009. In addition to these
electronic searches, the references of included studies were hand searched for any
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additional studies that met our inclusion criteria. A broad search strategy with no limits
on type of outcome was selected in order to minimize the risk of missing studies that had
been improperly indexed. The specific search strings are included as Appendix A.

2.2 Study Inclusion Criteria
The study inclusion criteria were formulated along a framework encompassing the
population of interest, the intervention of interest, and outcomes of interest. For a study to
be eligible for inclusion in the review, it had to meet all three criteria. Table 2.1 lists the
specific inclusion criteria.
Table 2.1 Inclusion Criteria for Studies
Population



Patients with ulcerative colitis ≥ 18 yrs of age

Intervention



Proctocolectomy with ileostomy
 OR
Restorative pouch procedure (regardless of type of
pouch) with or without protocolectomy
ONE OR MORE OF
Post-operative mortality
Post-operative complications
Early: wound infection, intra-abdominal sepsis,
anastomotic dehiscence, perianal sepsis
Late: pouchitis, anastomotic stricture, parastomal
hernia, pouch failure, bowel obstruction


Outcomes








Re-intervention/ re-operation (excision of pouch,
revision of ileostomy)



Bowel function (fecal incontinence, number of bowel
movements/day, need for pad, number of appliance
changes per day, need for incontinence pads, need for
anti-diarrheal medication)



Sexual dysfunction



Female: dyspareunia, reduced fertility
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Methodologic



Male: impotence, retrograde ejaculation



Quality of life



Study with more than 100 patients OR comparing
quality of life between pouch and end-ileostomy
Year of publication ≥ 1978
No previous publication with the same patients from
same institution
Report on baseline characteristics of the patients
undergoing procedure
English only language






In addition to the content specific inclusion criteria listed above, specific
methodologic criteria were applied to refine the inclusion of studies. The specific
inclusion criteria relating to population, intervention, and outcome need not be justified
given their self-evident nature, but methodologic criteria require some justification. For
the studies looking at clinical outcomes following either the IPAA procedure or
ileostomy, inclusion was limited to studies that reported on 100 patients or more. Larger
studies are more likely to provide a stable estimate of outcomes (complications), but
limiting the inclusion to studies with even higher numbers (> 1000) would likely result in
the inclusion of only a few studies from high volume centers which could bias the results,
as not all patients who would ultimately be using the decision aid would have access to
high volume centers. Outcomes following IPAA have been linked to surgeon and
institution volume, with lower volume centers having poorer results2. Thus limiting the
inclusion to studies with 100 patients or more strikes a balance between the desire to
include as many studies as possible, but also to include those with the most stable
estimates of outcome probabilities. Far fewer studies comparing quality of life between
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the two procedures have been published and no study size limitation was placed on the
inclusion of these studies.
Inclusion was also limited to studies that reported on baseline characteristics (age,
sex, underlying diagnosis) as it was necessary to assess these factors in order to assess
whether or not the patients undergoing the procedure met the other inclusion criteria
(population, intervention). Publications from the same institution reporting on the same
cohort of patients were also excluded. In cases where there were multiple publications
from the same institution, the most recent publication with the highest number of patients
was included, unless different outcomes were reported. This review was also limited to
publications reported in English. Given the large number of studies published on this
topic, we felt the added benefit of translating articles would not improve the conclusions
of the systematic review. Also there is evidence to suggest that the exclusion of nonEnglish language publications does not influence the ultimate conclusions of metaanalyses3, and that non-English language publications are often of poorer quality4.
No limitations were placed on study design (retrospective vs prospective), rather
this was included in the quality assessment of the studies. The use of broad inclusion
criteria with few limitations on study design has been recommended as the preferred
strategy when carrying out a meta-analyses of observational studies5.
All abstracts generated by the search strategies were reviewed independently by
two reviewers. Each reviewer indicated whether or not the study met the inclusion criteria
and agreement was measured using the kappa statistic. Any disagreements were resolved
by consensus, and if consensus was not met then a third reviewer was asked to decide.
Measurement of reviewer agreement has been recommended by the PRISMA statement
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as a way of enhancing the transparency and reliability of the methods used to screen and
select studies for inclusion into systematic reviews6.

2.3 Study Quality Assessment
Assessing the quality of included studies is an essential part of a systematic
review5, 6. There are two basic approaches to the assessment of study quality or “risk of
bias”, namely the use of scales or rating scores that reduce the assessment of a study’s
quality into a score, or the examination of key components of a study’s design and
relating individual elements of study design with quality. The attractiveness of the scale
or score approach lies in its ease of reporting, by attributing a number or rating to each
individual study. This rating can then be used as a weight in adjusting any subsequent
meta-analysis. Although attractive from a practical perspective, the use of scales and
scores has been criticized as over-simplifying the assessment of quality and potentially
introducing bias into the results when used as weights in analysis7, 8. Most scores are
constructed in an “ad hoc” fashion and lack validity, with various study elements being
combined that may or may not have an effect on study validity5, 9. An approach where
individual elements of study design are assessed and evaluated rather than summarized
into a score is the preferred method of study quality assessment5-7.
The assessment of study quality is not as well established for observational studies as
it is for randomized controlled trials5, 10. Within controlled-trials, specific elements of
study design including: concealment of allocation; blinding of outcome assessors,
participants, and patients; and proportion of patients lost to follow-up have all been
empirically linked to validity of results11-13. Although many tools for assessing study
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quality of observational studies exists, with one systematic review identifying 86 such
tools10, no one tool can be recommended over others given the lack of empirical evidence
relating specific design elements to study validity10, 14. As no consensus exists on the
specific method of quality assessment for observational studies, individual elements of
the included studies were evaluated for their impact on study quality.
Two systematic reviews on the topic of quality assessment in observational studies
came to similar conclusions about which items should be included in the quality
assessment of observational studies: methods of selecting patients, methods of measuring
outcome variables, adjustment for confounding, and completeness of follow-up10, 14.
These elements formed the basis of our assessment of study quality (Table 2.2). As most
of the studies ultimately included in the systematic review of outcomes following either
the IPAA or the ileostomy procedures were single center reports of case series with no
comparator, it was important to determine whether a significant selection bias was
occurring, namely that authors were only including their “best” cases as opposed to
including all patients that underwent a procedure when reporting their rates of
complications. To identify potential for selection bias, studies were classified as
consisting of consecutive patients or non-consecutive patients depending on the method
of patient recruitment. Studies were also classified as either prospective or retrospective
depending on the timing of patient recruitment relative to when the outcome occurred.
Studies that included consecutive patients recruited prospectively were considered to be
at less risk of selection bias compared with non-consecutive or retrospective studies.
Studies that did include a comparator group (quality of life studies comparing IPAA and
ileostomy) were evaluated as to whether or not the authors adjusted for confounding
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either in the design or the analysis of the study. Studies that adjusted for confounding
were considered to be at less risk of bias. Given the large number of outcomes of interest
to the systematic reviews (most complications following IPAA or ileostomy) it was
impractical to evaluate specific definitions for specific outcomes. Rather, studies were
classified based on whether the outcomes listed were clearly defined. Studies that applied
specific definitions when assessing outcomes were considered to be at less risk of bias, as
specific definition of outcomes allows the application of systematic outcome assessment,
and limits subjective interpretation by the individual outcome assessor. Although blinded
outcome assessment has been linked to study validity12, 13, this measure was not
applicable to most studies in our review given the predominance of single group case
series.
For the group of studies reporting on quality of life comparisons between IPAA and
ileostomy, whether or not the study utilized a validated quality of life measure was
recorded. Studies that utilized a validated measure of quality of life and made reference to
the method of validation were considered to be of less risk of bias when compared to
studies that utilized non-validated measures of quality of life15.
Loss to follow-up was also considered a quality measure, as controlled-trial literature
has shown it to be associated with study validity. Length of follow-up was also included,
as many of the important outcomes following either procedure can be time dependent.
For example, 45% of patients who will ultimately develop pouchitis, an important
complication following IPAA, will only do so at least 6 months following the
procedure16. Along with completeness and length of follow-up, we considered studies
that had a standardized protocol for follow-up, meaning routine clinical assessments at
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pre-specified time points, to be more likely to accurately detect and report complications
following either procedure and thus be at less risk of bias.

Table 2.2 Study Elements Evaluated for Quality
Quality Criteria
Selection

Categories
 Non-consecutive: if patients were recruited from a
specific clinic/ institution but no mention is made if they
are consecutive or represent all patients from that clinic
over a specified time period
 Consecutive: if patients were recruited in a consecutive
manner OR represent all patients who presented to a
specified clinic/institution over a specified time period



Confounding






Outcome
criteria clearly
defined





Quality of life
instrument




Loss to follow-up



Retrospective: If the study reports on patients whose
outcomes occurred before the study began
Prospective: If the study reports on patients whose
outcomes occurred after the study began

Adjustment: if the authors adjusted either in the design
(matching) or analysis (multivariable methods,
stratification) of their study for the presence of
confounders.
No adjustment
No comparator group: if the study did not include a
comparator group
All: if the authors defined their criteria for all the
outcomes reported in the study
Some: if the authors only defined some of the outcomes
reported in the study
None: if none of the reported outcomes were defined

Validated: If study reports on the validation method or
referenced a study which details the validation method
used
Not Validated: No mention of validation of the
instrument/ measure
% of patients not accounted for in the results
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Length of follow-up



mean or median length of follow-up reported in months

Follow-up protocol



Standardized: Standardized follow-up protocol with
routine visits at pre-specified time points
Non-standardized: Follow-up was not completed in a
standardized fashion or no mention of follow-up
procedures



Each element of study quality was reported for the individual studies and their
influence on the results was explored using sensitivity analyses.
2.4 Results of Study Search
The search strategy outlined previously was last updated on January 30, 2009. In
addition to these electronic searches, the references of included studies were hand
searched for any additional studies that met our inclusion criteria. Figure 2.1 summarizes
the results of the searches. Once duplicates were removed, 3920 distinct abstracts were
independently reviewed by two reviewers and any study that either party felt met
inclusion criteria was selected for full text review1. Of the 3920 abstracts, 411 were
ultimately selected for full text review. Of these 411 abstracts, the majority were
excluded from final study inclusion. The most common reason for exclusion was a
publication dealing with the same cohort of patients published at different time points. In
cases were multiple publications dealt with the same cohort of patients, the study with the
inclusion of the larger number of patients was used in the review. Studies meeting
inclusion were divided into three groups that form the basis of the three meta-analyses to
follow. Chapter three of this work will deal with the results of the literature review
surrounding quality of life comparisons between IPAA and ileosotmy, while chapters

1

A file containing the list of abstracts reviewed is available from the author as it was too large to included
as an appendix.
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four and five will summarize the results of the meta-analyses of studies reporting on
outcomes following IPAA, and ileostomy respectively. The first review is necessary as
part of the justification process for a decision aid, if one strategy is clearly superior to the
other in terms of quality of life then it throws the very idea of a decision aid into question,
and at the very least, any important difference in quality of life must be included in the
aid. The other two meta-analyses are necessary to populate the decision aid with outcome
probabilities.
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Medline (n =1938)

Embase (n =2529)

Records identified through
database searching
(n =4659)

CINAHL (n =127)

Cochrane (n =65)

Records after duplicates removed
(n = 3920)

Records screened
(n = 3920)

Full-text articles assessed
for eligibility
(n = 411)

Studies included in
systematic review of
Quality of life between
IPAA and ileostomy
(n = 9)

Records excluded
(n = 3509)

Full-text articles excluded
(n = 324)
Reasons for exclusion:
Paper with duplicate cohort of patients (n = 124)
Paper with < 100 patients (n = 57)
Review paper only (n = 41)
Report on subgroup of patients only (n = 38)
Non-English language paper (n = 22)
Did not report on the outcomes of interest
(n = 25)
Wrong intervention (n = 17)

Studies included in
systematic review of IPAA
outcomes
(n = 67)

Figure 2.1 PRISMA6 Flow Diagram of Identified Studies

Studies included in
systematic review of
ileostomy outcomes
(n = 11)
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CHAPTER THREE-A SYSTEMATIC REVIEW OF STUDIES COMPARING
QUALITY OF LIFE BETWEEN IPAA AND ILEOSTOMY
3.0 Introduction
Whether ulcerative colitis is treated with a proctocolectomy and ileostomy or with
an ileal pouch-anal anastomosis (IPAA), the resulting control of disease, namely the
removal of the diseased colon and rectum is the same. What differs is the post-operative
experience of the patient and the impact each option has on the patient’s day to day life.
In patients with inflammatory bowel disease who have not had surgery, fears and worries
surrounding surgery and the potential need for an ostomy appliance are most prominent
when compared to other concerns1. Patients with active, symptomatic ulcerative colitis
generally have worse health-related quality of life (HRQOL) than healthy controls2-4.
Severity of disease activity is one of the most important determinants of health-related
quality of life in patients with ulcerative colitis2, 5-7. Removing the colon and rectum in
patients with ulcerative colitis is often curative, and several studies have documented
similar HRQOL between patients following colectomy and the general population8-11.
Studies examining changes in HRQOL between preoperative and postoperative patients
have similarly shown an improvement following colectomy12,

13

. Muir et al in a

prospective study of patients undergoing IPAA showed an improvement in both diseasespecific and generic measures of health-related quality of life when pre and postoperative scores were compared12. These findings have not been universal as Berndtsson
and Oresland showed no difference in generic HRQOL between preoperative and
postoperative patients undergoing IPAA, and only a modest gain in disease-specific
HRQOL14. With intractability of disease as the most common indication for
proctocolectomy, most patients can expect to have improved HRQOL following surgery.
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The question becomes: Does the form of intestinal reconstruction, IPAA or ileostomy,
influence the HRQOL of these patients or is the gain in HRQOL independent of which
procedure patients receive?
In order to justify the design and application of a decision aid to help patients
select which reconstructive option they would prefer, it is necessary to explore the
specific effects each has on HRQOL. If one option is clearly superior in regards to
HRQOL, then perhaps the role of a decision aid becomes less important as one option
may be recommended over the other on the basis of improved HRQOL. If, on the other
hand, they are shown to be largely equivalent then helping patients make the choice that
is most in keeping with their values and expectations is of paramount importance and the
role of a decision aid becomes vital in facilitating such a process. What follows is a
systematic review of studies comparing proctocolectomy with IPAA or ileostomy and
their effects on HRQOL. Before describing the methodology and results, a brief
introduction to the concept of health-related quality of life is necessary to provide context
for the remainder of the chapter.

3.1 Health-Related Quality of Life
Health-related quality of life seeks to measure the functional impact a disease and
its therapy have on a patient’s day to day life15. It moves beyond measuring the specific
disease state (symptoms, complications) by encompassing behaviours, emotional
attitudes, and perspectives of an individual and how they related to their current state of
health16. Measuring HRQOL is important as two patients may have identical disease
severity yet one will have a job and a healthy social life, while the other is unemployed,
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depressed, and on disability. Capturing and measuring these differences is the purpose of
HRQOL assessment.
3.1.1 HRQOL Measurement
HROQL instruments can be classified into three main types: global, generic, and
specific16. Global measures consist of a single question or score used to summarize
overall quality of life. Often consisting of simple questions like “How is your quality of
life?” these measures, although easy to administer and report, are often insensitive to
smaller changes in quality of life and do not provide any information on specific areas of
dysfunction17. Generic and specific instruments are questionnaires containing items that
are grouped into domains. A domain or dimension is a specific area of
experience/behaviour that the instrument is attempting to measure15. The items
(questions) forming the individual domains are combined into scores representing each
domain, thus allowing the researcher the ability to assess the impact of a therapy or
disease on a specific domain. These domain scores are then combined to provide a
summary score for that patient’s HRQOL.
The classic example of a generic measure is the Medical Outcomes Survey Study
36-Item Short Form (SF-36)18. The SF-36 is a self-administered health survey composed
of 36 items organized among 8 domains: bodily pain, general health, mental health,
physical functioning, role-emotional, role-physical, social functioning, and vitality. The
resulting score ranges from 0 (worst) to 100 (best). The advantages of such a scoring
system lie in its applicability across patient populations and disease states.
Another type of generic instrument is one that measures utility, which is defined
as a patient’s preference for a specific disease state and/or treatment19. These measures
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are rooted in decision theory and are typically used in economic analyses as they
summarize HRQOL into a single number, usually from 0 (death) to 1 (perfect health).
They can be combined with cost data to produce cost-utility analyses and are useful when
evaluating health care programmes. Although useful, utility measures are often
unresponsive to subtler changes in HRQOL and they do not show in which domain
improvements or deteriorations occur15.
Bernklev et al showed that when the SF-36 was applied to patients with
ulcerative colitis, scores were significantly lower in 6 of the 8 domains when compared to
normal population values4. Although useful in patients with ulcerative colitis, generic
measures such as the SF-36 have been criticized for their lack of responsiveness, namely
the ability to detect smaller changes in HRQOL related to disease activity or therapy over
time4,15,20. To overcome this limitation, disease specific instruments have been developed
to detect smaller yet clinically meaningful changes in HRQOL among patients with
inflammatory bowel disease. The most commonly used disease specific instrument is the
Inflammatory Bowel Disease Questionnaire (IBDQ)21. The IBDQ is an interviewer or
self-administered questionnaire consisting of 32 questions organized along 4 domains:
bowel symptoms, emotional functioning, social functioning and systemic symptoms, with
each question being scored 1-7 resulting in a range of 32-224; with higher scores
indicative of better HRQOL. The recommended approach is to utilize both a generic
measure and a disease specific measure when evaluating the impact of a disease or
therapy on HRQOL4, 15, 17, 20. Table 3.1 summarizes the most common instruments used
in evaluating quality of life in inflammatory disease patients.
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Table 3.1 Quality of Life Instruments Used in Ulcerative Colitis
Instrument
Generic
SF-3618

Items/Domains

Scoring

36 questions organized into 8 domains: 0 (worst)-100 (best)
bodily pain, general health, mental health,
physical functioning, role-emotional, rolephysical, social functioning, and vitality.

Sickness impact 136 questions evaluating every day 0 (most dysfunction)profile (SIP)22
activities among 12 categories: sleep and 100 (no dysfunction)
rest, emotional behaviour, body care, home
management, mobility, social interaction,
ambulation, alertness, communication,
work, recreation, eating, these are further
grouped along 2 domains, physical and
psychosocial.
Utility
Time Trade-Off Based on standard gamble theory, patients 0 (death) – 1.0 (perfect
Technique
are asked to trade-off time spent in a health)
(TTOT)23
disease state with time spent being
perfectly healthy, the resulting point of
indifference (amount of time being healthy
equivalent to normal life span in disease
state) is translated into an index between 01.
Disease Specific
Inflammatory
Bowel Disease
Questionnaire
(IBDQ)21

32 question interviewer or self- Each question (1-7), 32administered questionnaire evaluating 4 224 total score (higher
domains: bowel symptoms, emotional score = better HRQOL)
function, social function, systemic
symptoms.

Rating Form for 25 questions evaluating 5 domains: impact 0-100 (higher score =
IBD
Patient of disease, sexual intimacy, complications worse HRQOL)
Concerns
of disease, body stigma.
(RFIPC)24
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3.1.2 Characteristics of HRQOL Instruments
A methodologically robust HRQOL instrument must at the very least measure
what it is intended to measure, namely quality of life. The difficulty arises as no “gold
standard” exists for the measurement of quality of life15, thus newly developed
instruments cannot simply be validated by a comparison to a gold standard. To overcome
this issue, concepts surrounding “surrogate” measures of validity have been borrowed
from the psychological literature and applied to the validation of instruments intended to
measure HRQOL. Face validity implies that an instrument appears to measure what it is
intended to measure, while content validity refers to whether an instrument
comprehensively examines the domains of interest relating to the intended concept to be
measured25. These aspects of validity are not quantitatively evaluated, rather they are the
result of careful review and consideration of the items within the instrument often by a
panel of experts or patient focus groups16. Construct validity refers to how an instrument
measures or behaves in relation to the theoretical construct it is supposed to measure25. It
is evaluated by comparing changes in the instrument to changes in some other marker of
disease, seeing if it behaves as predicted based on its theoretical construct. For example,
an instrument used to measure pain (its theoretical construct) should correlate with
changes in the amount of pain medication used. Criterion validity refers to an instruments
ability to relate to a similar questionnaire intended to measure similar domains 16. For
example, a new disease specific measure of HRQOL could be compared to an established
reference, such as the IBDQ, to see if the two are congruent. For a new instrument to be
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deemed valid, it should satisfy these validity concepts. Table 3.2 summarizes properties
of methodologically sound HRQOL measures.
Table 3.2 Desirable Properties of HRQOL Measures.
Property

Concept

Validity
Face validity

Instrument evaluates intended concept

Content validity

Instrument is representative of all areas of interest being made up
of multiple domains comprehensively representing the concept
being studied

Construct validity

Instrument behaves as predicted by its theoretical construct when
compared to some other marker of disease or therapy

Criterion validity

Instrument behaves congruently when compared with some
accepted reference standard that measures similar concepts

Reliability
Test-retest reliability Instrument should have consistent results when applied
repeatedly to the same patient and variation between patients
should be greater than variability within patients
Internal Consistency

Items within a domain should correlate with each other

An instrument must not only be valid but must also display reliability when
repeatedly applied to the same patients (test-retest reliability), have internal consistency
among its various domains, and be responsive to clinically meaningful changes in
HRQOL15-17. In a systematic review of instruments used for the measurement of
HRQOL among patients with inflammatory bowel disease, Pallis et al identified two
disease specific measures, the IBDQ and the RFIPC that have been shown to be valid and
reliable26. As part of the systematic review of studies comparing HRQOL between
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patients with an IPAA and patients with an ileostomy, we sought not only to summarize
their results but also to evaluate whether they had measured HRQOL using a validated
instrument.
3.2 Methods
Search Strategy
The details of the search strategy are outlined in chapter two of the thesis. Given
the smaller number of studies in this group we did not limit ourselves to studies with at
least 100 patients, but rather included all studies that compared health-related quality of
life between patients undergoing IPAA or ileostomy. All titles and abstracts were
independently reviewed by two reviewers, and any study that either reviewer deemed as
potentially eligible was selected for full text review. Study inclusion was then assessed
independently with any disagreement resolved by consensus. Specific study inclusion
criteria are detailed in chapter two of this work.
Data Extraction
All information was extracted independently by two reviewers with any
disagreements resolved by consensus. Data pertaining to details about the patients (age,
sex), intervention (IPAA or ileostomy, complication rate), length of follow-up, and
quality of life measures used were extracted. Numerical results of the various HRQOL
instruments were also extracted along with their statistical significance (p-value) and the
conclusions of the authors.
Quality Assessment
The method of assessment and justification for study quality evaluation is also
found in chapter two of this work. However, this was expanded for the quality of life
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studies to include an assessment of the validity of the instruments used in each study
along the criteria in Table 3.2. HRQOL measures were evaluated based on whether the
authors indicated in their study, or made reference to other studies, where the validity and
reliability of their chosen HRQOL instrument had been established. Instruments were
considered to have face validity if some description of the method used to decide on what
elements to include in the measure were included in the work or in the references; while
instruments were considered to have content validity if they were made up of multidomain scores comprehensively covering the concept of interest. Construct validity was
established if the authors described or made reference to studies that compared the
instrument to some marker of disease or therapy. Criterion validity was established if the
instrument was compared to some other established HRQOL measure. Where applicable
the validation references were extracted. Instruments were considered to be overall valid
if the authors displayed or made reference to the demonstration of construct and/or
criterion validity, as these are the most rigorous methods of establishing validity15.
Analysis
Although we had originally intended to meta-analyze the overall scores and
domain specific scores of the included studies using weighted mean difference27, where
the difference between two groups is adjusted for by study size. We deemed that there
was too much heterogeneity across studies in terms of different HRQOL instruments and
the way the results were reported (some mean, some median) to allow for quantitative
analysis. Instead, the individual study results are presented in a table with the conclusions
reached by the authors of the studies.
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3.3 Results
We identified 9 studies that compared HRQOL between patients with ulcerative
colitis that had undergone either an ileal pouch-anal anastomosis procedure or an
ileostomy. Agreement between reviewers for this subset of studies was excellent, with no
disagreements about study inclusion (kappa = 1.0). Table 3.3 summarizes the study
characteristics of included studies.
3.3.1 Quality of Included Studies
The quality of the studies varied widely with only three studies including
consecutive patients and only two being prospective. Two studies adjusted for
confounding, one in their analysis using a logistic regression, and the other in their design
through matching patients from both groups for known confounders of HRQOL. Losses
to follow-up, or in this case response rates to HRQOL questionnaires, were generally
poor with all but three studies having >20% non-response rates. Table 3.4 summarizes
the differences in study quality.
3.3.2 Validity of HRQOL Instruments Used
Of the included studies, 5 used validated measures of HRQOL, while four studies
used non-validated measures. Three studies used the validated, generic SF-36 measure,
while three studies utilized the validated, disease-specific IBDQ measure. Of the nonvalidated measures, most were global assessments based on a yes/no answer to a question
related to either social restriction or overall satisfaction. Liddell et al used a selfdeveloped score measure to assess patient satisfaction28. This assessed the degree of
improvement with surgery over eight domains: social activities, sports activities,
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housework, recreation, family relationships, sex, travel, and work. Although this measure
met the criteria for face and content validity, no mention of methods to test construct or
criterion validity were described. In a similar self-developed, non-validated score based
instrument, Pemberton et al used a questionnaire consisting of seven domains: sports,
sexual life, social activities, recreation, work around the house, family relationships, and
travel; to assess the impact of surgery on restrictions in each domain29. Again, construct
and criterion validity were not assessed. McLeod et al utilized two validated utility
measures to assess the impact of each procedure on overall quality of life, as well as a
validated generic measure, the Sickness Impact Profile30.

3.3.3 Comparison of IPAA to Ileostomy Patients

Global instruments
Studies using global measures to compare HRQL between ileostomy and IPAA
patients found there were no significant difference between patients overall satisfaction
(95 vs 93%)29, ability to return to work or school (98 vs 94%)29, and overall quality of life
(87 vs 93%)31. Similar results were described using two validated utility measures with
no difference between groups30. Emblem et al described significantly more societal
restriction among ileostomy patients using a non-validated questionnaire (67% vs 0%)32.

Generic instruments
Of the three studies using the SF-36, no difference in overall scores was found
between the two groups3, 33, 34. The only domain-specific difference was described by
Nordin et al who found worse social functioning among the IPAA patients3. McLeod et al
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found similar results with no difference in overall scores using the Sickness Impact
Profile30. Two non-validated generic instruments showed mixed results. Liddell’s
Lifestyle Satisfaction Score failed to detect a difference between the two groups, either in
its summative score or in the individual domain scores28. In contrast, Pemberton’s
Performance Score, which contained similar elements to Liddell’s score, found
significant worse performance scores among ileostomy patients among all seven domains
(sports, sexual life, social activities, recreation, work around the house, family
relationships, and travel)29.
Disease-specific instruments
Of the three studies using the IBDQ, no differences in overall scores were found
between the two groups3, 34, 35. Only one study identified a difference in domain specific
scores, Nordin et al described worse social functioning and systemic symptoms among
the IPAA patients3. O’Bichere et al using a self-developed, non-validated, disease
specific visual analogue scale (VAS) found IPAA patient to have worse altered bowel
habits and more restrictions on diet than patients with ileostomies; while ileostomy
patients had worse body image33. Table 3.6 summarizes the study results and conclusions.
3.4 Discussion
Health-related quality of life is a measure of a patient’s perception of the impact a
disease or its therapy has on their illness experience and functional status36. We identified
nine studies that compared HRQOL between ileostomy and IPAA patients. No study
identified an overall difference in quality of life between the two groups. Overall markers
of quality of life, whether they are global, non-validated, generic, or disease specific, all
indicate that patients with ulcerative colitis who undergo proctocolectomy have good
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HRQOL regardless of which reconstructive option they undergo (ileostomy or IPAA).
This is in keeping with the concept that removal of the diseased colon is what improves a
patient’s quality of life following surgery, not the restoration of anal defecation.
Although the restoration of anal defection via an IPAA has been perceived to
result in an improved quality of life when compared to an ileostomy, as indicated by
some modern narrative reviews37, 38, this claim is not substantiated by a critical review of
the literature. In fact, older literature indicates a high degree of satisfaction among
patients with ileostomies. In a survey of 273 patients with ileostomies, Roy et al reported
that 92% perceived themselves to have a normal lifestyle, and 89% indicated they had
good or excellent health39. In a similar survey of 273 patients with ileostomies from the
Cleveland Clinic, 74% of patients reported that they had normal lives40. Further evidence
that removal of the diseased colon is the key to good post-operative quality of life comes
from a study by Weinryb et al where patients having undergone a staged IPAA had their
quality of life assessed before and after their temporary ileostomies were closed. Using a
validated generic measure, the Psychological Adjustment to Illness Scale (PAIS)41, the
authors found no further improvement in HRQOL following closure of ileostomy42, 43.
Studies have documented an improvement in HRQOL following proctocolectomy
in patients with ulcerative colitis primarily related to control of their symptoms and
disease12, 30, 44. Of note, these benefits are less apparent among patients with familial
adenomatous polyposis (FAP) who undergo IPAA. FAP is an inherited disorder
characterized by the development of hundreds of polyps and a high risk of colon cancer,
often warranting a prophylactic proctocolectomy as most patients will ultimately develop
colon cancer 45. These patients often receive an IPAA but they are not generally
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symptomatic or ill prior to the procedure, unlike ulcerative colitis patients. Studies
comparing postoperative quality of life among FAP and ulcerative colitis patients have
consistently found a worse postoperative quality of life among FAP patients46, 47. In a
study of 64 patients, 10 of whom had FAP, HRQOL assessed by the Cleveland Clinic
Global Quality of life scale8 found significantly worse quality of life among FAP
patients46, despite improved functional results in the FAP group.
Although we found no overall differences in HRQOL, some domain/item specific
differences were observed between IPAA and ileostomy patients. Pemberton et al using a
self-developed performance status score found more functional restriction among patients
with ileostomies, particularly among the sexual activity, sports, social activities, and
travel domains29. In contrast, Nordin et al, using the well validated IBDQ and SF-36
found worse social functioning among the IPAA patients on both items3. These disparate
findings may be explained by the effects of morbidity on quality of life. In Pemberton’s
study, patients with ileosotomies had a much higher morbidity (complication) rate (22%
vs 11%), which likely contributed to their worse functioning. The use of different
instruments may also explain the contrasting results, although this is difficult to assess
given the lack of validation of Pemberton’s performance score. O’Bichere also found
worse domain specific scores with IPAA patients indicating that their procedure more
negatively impacted on their bowel habits and diet when compared to ileostomy
patients33. However, this was based on a non-validated self-developed score, and thus it is
difficult to properly compare these results to those obtained using validated instruments.
No study using a validated generic or disease specific instrument identified greater
functional restriction among patients with ileostomies.
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One consistent finding, however, was the reduced body image associated with an
ileostomy. O’Bichere found a reduced body image among ileostomy patients when
measured on their self-developed visual analogue score, although this did not result in a
reduced overall quality of life when combined to produce a summative score, as it was
offset by problems with pouch functioning among the IPAA patients33. CamilleriBrennan, using a self-developed, non-validated questionnaire also found reduced body
image among patients with ileostomies34. Liddell et al using a validated multidimensional
Body Self-Relations Questionnaire48 also found reduced body image among patients with
ileostomies28. Despite these findings, no study identified any overall differences in
quality of life, indicating that the overall impact of reduced body image is unlikely to be
of any great functional consequence to these patients.
Ultimately, any systematic review is limited by the quality of its included studies.
The quality of the nine studies varied widely, not only in their design (Table 3.4), but also
in the quality of their method of HRQOL assessment (Table 3.5). These differences made
comparisons between studies difficult to interpret. The most important aspect of quality is
the use of validated measures of HRQOL. Statistical tests of the results of non-validated
instruments are of little value and hazardous to interpret36. The studies of the highest
methodological quality used both a validated generic and a validated disease specific
instrument in their assessment of HRQOL; both identified no difference in HRQOL
between IPAA and ileostomy patients. In the remaining studies, one used a validated
generic measure and two validated utility measures, one used a validated generic measure
combined with a non-validated disease specific instrument, one used a validated disease
specific instrument only, and 4 used non-validated global measures. The design of studies
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varied greatly with only three being prospective and six being retrospective. Only two
studies adjusted for confounding. Pemberton et al adjusted the results of their
performance score using a logistic regression accounting for differences in age, sex,
duration of disease, and re-operation, although there performance score was not a
validated measure29. Camilleri-Brennan’s study was of the highest methodologic quality
as they combined a prospective design, adjustment for confounding, standardized followup, and validated HRQL assessment (generic and disease specific)34. They matched
patients in both groups for age, sex, socioeconomic status, and time since surgery and
found no difference in HRQOL in either the generic or disease-specific instruments.
All but one study had suboptimal response rates to the questionnaires, with rates
ranging from 98% to 58.1%. This is an important consideration as non-responders are
often different in terms of characteristics than responders, and this can introduce bias into
the results49. The only study to compare responders to non-responders identified no major
differences in demographics or complications between the two groups31, thus the impact
of this potential bias is difficult to determine.
The studies were generally limited by their small sample size with only one study
containing greater than 100 patients per group. This may have resulted in under-powered
comparisons. One way to overcome this would have been a quantitative meta-analysis of
the results. This was not possible as the studies used different measures of HRQOL; and
in the studies that did use similar measures, the results were reported differently (mean vs
median), not allowing for meta-analysis. One approach would have been to combine the
results of different measures through standardization, although this approach has been
criticised for introducing bias as the most responsive instruments will carry
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disproportionately more weight in the analysis50. Despite small numbers, disease-specific
measures such as the IBDQ have been shown to be responsive enough to be suitable for
even small trials (n=20)36.
This is the only systematic review looking specifically at the question of whether
IPAA patients have improved health-related quality of life when compared to patients
with ileostomies. Despite its systematic nature, this review does have several limitations.
The first is the variable quality of the studies as discussed above. The second is the
inability to quantitatively combine the results into a meta-analysis. Although this may
have improved the power of the comparison, it may have introduced bias as the studies
were fairly heterogeneous in terms of their clinical characteristics (morbidity rates),
methods of HRQL assessment, length of follow-up, and methodological quality. Thirdly,
no specific measures were taken to account for publication bias. Publication bias usually
results from not including non-published studies that are more likely to have nonsignificant results51. This is unlikely to be a factor as the major substantive conclusion of
this review is that no difference exists between the groups. A final limitation is the
inclusion of English-only language studies, the justification for and rationale can be
found in chapter two of this work.
Although limited by variable study quality and small sample sizes, the current
literature does not support the assumption that the more advanced IPAA procedure leads
to an increase in quality of life when compared to the conventional ileostomy. Both
appear equivalent in terms of overall quality of life, although ileostomy patients have
poorer body image. These findings provide further rationale and justification for the
development of a patient decision aid to help patients decide between the two
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reconstructive options. This literature supports the concept that patients who select a
certain option are satisfied with their choice and generally enjoy a good HRQOL. Despite
high complication rates following IPAA, Skarsgard et al showed that 92% of patients
would choose to undergo a pouch procedure again52. Thus empowering and facilitating
this choice, rather than recommending one option over the other is the right way to
approach the therapeutic decision between an IPAA and an ileostomy.
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TABLE 3.3. Quality of Life Study Characteristics
Study
(author/year)

Country

HRQOL
measure

Groups

N

Age
(mean, range, yrs)

Male (%)

Morbidity rate
(%)

Emblem
(1988)32

Norway

Social restriction

IPAA

19

27 (23-38)

53

21

Follow-up
(mean,
months)
48

Ileostomy

35

30 (26-35)

60

71

58

Overall
satisfaction,
return to work or
school,
Performance
status
Time trade-off
(TTOT)
Direct
questioning of
objectives
(DQO)
Sickness-impact
profile (SIP)

IPAA

298

32*

51

11

47*

Ileostomy

406

38

59

22

104

IPAA

37

36 ± 9

49

8.1†

NR

Ileostomy

28

39 ± 13

54

18

NR

Lifestyle
satisfaction

IPAA

25

33.2 ± 7

40

NR

40

Ileostomy

10

51 ± 14

40

NR

47

Inflammatory
Bowel Disease
Questionnaire
(IBDQ)

IPAA

55

31

45

49

12

Ileostomy

12

52

60

8

12

Visual analogue
scale (VAS)

IPAA

30

Ileostomy

30

43 (22-71)‡

44

NR

13

Pemberton
(1989)29

McLeod
(1991)30

Liddell (1995)28

Jimmo (1998)35

O’Bichere
(2000)33

USA

Canada

Canada

USA

UK

Short-Form 36
(SF-36)
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Seidel (2000)31

Nordin (2002)3

CamilleriBrennan
(2003)34

USA

Sweden

Scotland

Overall quality
of life

SF-36
IBDQ

SF-36
IBDQ

IPAA

55

31.2 ± 1.3

55

63

Ileostomy

31

44.8 ± 3.7

48

16

30.6 ± 3.5‡

IPAA

57

Ileostomy

42

46 (20-70)

48

NR

NR

IPAA

19

41*

63

21.1

41*

Ileostomy

19

41

63

42.1

43

* median; † rate of re-operation; ‡for both groups combined; NR not recorded
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TABLE 3.4 Study Quality Assessment
Study
(author/year)

Consecutive
patients

Study type

Emblem (1988)32

No

Retrospective

Adjustment
for
confounding
No

Pemberton (1989)29

Yes

Retrospective

McLeod (1991)30

No

Liddell (1995)28

Response
Rate

Validated QOL
measure

100%

No

Yes2

81%

No

Retrospective

No

98%

Yes

No

Retrospective

No

87.5%

No

Jimmo (1998)35

Yes

Prospective

No

79%

Yes

O’Bichere (2000)33

No

Retrospective

No

68.9%

Yes

Seidel (2000)31

Yes

Retrospective

No

58.1%

No

Nordin (2002)3

No

Retrospective

No

69.3%

Yes

Camilleri-Brennan
(2003)34

No

Prospective

Yes3

76%

Yes

2

Pemberton et al adjusted for confounding in their analysis using a logistic regression for performance scores, adjusting for age, sex, duration of disease, and
subsequent re-operation.
3
Camilleri-Brennan et al adjusted for confounding in their design by matching the two groups for age, sex, time since surgery, and socioeconomic status,
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TABLE 3.5. Properties of Quality of Life Instruments
Study
(author/year)
Emblem
(1988)32

HRQOL measure
(type)
Societal restriction
(global)

Face
validity
No

Content
validity
No

Construct
validity
No

Criterion
validity
No

Internal
consistency
NA

Reliability
No

-

Pemberton
(1989)29

Overall satisfaction,
Return to work or
school,
Performance status
(generic)
TTOT (utility)

No

No

No

No

NA

No

-

Yes

Yes

No

No

No

No

Yes

Yes

Yes

Yes

NA

Yes

DQO (utility)

Yes

Yes

Yes

Yes

NA

Yes

SIP (generic)
(range 0-100)
Lifestyle
satisfaction
(generic)
IBDQ (disease
specific)
SF-36 (generic)

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

No

No

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

VAS (diseasespecific)
Overall quality of
life (global)
SF-36 (generic)

No

No

No

No

No

No

No

No

No

No

No

No

Yes

Yes

Yes

Yes

Yes

Yes

IBDQ (disease
specific)

Yes

Yes

Yes

Yes

Yes

Yes

SF-36 (generic)
IBDQ (diseasespecific)

Yes
Yes

Yes
Yes

Yes
Yes

Yes
Yes

Yes
Yes

Yes
Yes

McLeod
(1991)30

Liddell
(1995)28
Jimmo (1998)35
O’Bichere
(2000)33
Seidel (2000)31
Nordin (2002)3

CamilleriBrennan
(2003)34

Validation references

Bergner et al22
Churchill et al53
Detsky et al54
Torrance et al23

Guyatt et al21
Irvine et al25
Ware et al18
McHorney et al55, 56

Ware et al18McHorney
et al55, 56
Guyatt et al21
Irvine et al25
Ware et al18McHorney
et al55, 56
Guyatt et al21
Irvine et al25
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TABLE 3.6 Quality of Life Study Results
Study
(author/year)
Emblem
(1988)32

Groups (n)

QOL measure

IPAA (19)

Societal restriction
(%yes)

Numerical results
IPPA
Ileostomy
0%
67%

p-value

Conclusions

<0.01

Ileostomy patients suffered greater social
restriction then IPAA patients

95%

93%

NS

98%

94%

NS

Overall satisfaction was similar between
the two groups although IPAA patients
had improved performance scores when
compared to ileostomy patients4

0.95 ± 0.15

0.97 ± 0.08

<0.05
NS

0.87 ± 0.18

0.89 ± 0.15

NS

1.2 ± 2.3

3.1 ± 5.0

NS

Ileostomy (35)
Pemberton
(1989)29

IPAA (298)
Ileostomy (496)

McLeod
(1991)30

IPAA (37)
Ileostomy (28)

Liddell
(1995)28

IPAA (25)
Ileostomy (10)

4

Overall satisfaction
(%yes)
Return to work or school
(%yes)
Performance score1
TTOT (0-1.0)
(mean ±SD)
DQO (0-1.0)
(mean ±SD)
SIP (0-100)
(mean ±SD)
Lifestyle Satisfaction5
Overall satisfaction (1-7)
(mean ± SD)

5.48 ± 1.56

5.7 ± 1.34

NS

No difference in QOL using two utility
measures and one generic measure
between the two groups. Even a
subgroup analysis of ileostomy patients
contemplating a change to IPAA showed
no difference.
No difference in overall satisfaction
between the two groups. Comparison of
the seven sub-categories2 failed to reveal
any differences as well.

Pemberton et al used a self- developed, un-validated, performance score measure as a way to determine the impact of each surgical procedure on daily life. It
consisted of seven categories (sports, sexual life, social activities, recreation, work around the house, family relationships, and travel) each assessed with a 5point Likert scale. The results were only presented graphically, thus they were not extractable. In each category, IPAA patients showed significantly less
restriction than ileostomy patients.
5
Liddell et al used a self-developed, un-validated score-based questionnaire to assess patient satisfaction. Eight domains and an overall assessment were
explored: social activities, sports activities, housework, recreation, family relationships, sex, travel, and work; and each was given a score based on a 7-point
Likert scale (markedly worse to marked improvement).
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Jimmo (1998)35

IPAA (55)

IBDQ (32-224)
(mean ±SD)

205 ± 206

200 ± 25

0.49

SF-36 (0-100)
(median)
Health perception
Physical functioning
Role-physical
Role-emotional
Social functioning
Mental Health
Bodily pain
Energy/vitality

57
90
88
100
88
68
90
43

55
80
75
100
88
76
80
53

NS
NS
NS
NS
NS
NS
NS
NS

VAS (1-10)7 (median)
Body image
Altered bowel emptying
Odour
Noise
Sexual relationship
Clothes
Diet

5
8
5
5.5
5
3.5
5.5

8
5
8
6
7
3
2

NS
<0.05
NS
NS
NS
NS
<0.05

87

93

NS

Ileostomy (12)
O’Bichere
(2000)33

IPAA (30)
Ileostomy (30)

Seidel (2000)31

IPAA (55)

Nordin (2002)3

Ileostomy (31)
IPAA (57)
Ileostomy (42)

6

Overall quality of life
Better since operation
(always %)
SF-36 (0-100)
(mean)
Overall health
Physical functioning
Role-physical
Role-emotional
Social functioning
Mental Health

NR
NR
NR
NR
70.2
NR

NR
NR
NR
NR
89.3
NR

<0.05

No difference in disease-specific quality
of life between the two groups. No
difference demonstrated when individual
categories of IBDQ were compared
No difference was found in HRQOL
using the SF-36 instrument between the
two groups. The negative impact altered
bowel habits and problems with pouch
functioning are highlighted by the
differences in the VAS domain of bowel
emptying. While the negative effects of
the ileosotomy on body image are also
evident as these patients scored worse on
the VAS.

No difference between groups in overall
quality of life.
Patients with IPAA actually scored worse
on some domains of both the generic and
disease specific measures of HRQL.
IPAA patients had worse social
functioning, more bowel symptoms, and
worse emotional functioning than
patients with ileostomies. There were no
differences in the remaining domains of

Values extrapolated from figure.
O’Bichere et al used a self-developed, non-validated 10-point visual analogue scale to assess how problematic patients saw the surgery in relation to each
domain: body image, altered bowel emptying, odour, noise, sexual relationship, clothes, diet. Each was given a score from 1 (least problematic) to 10 (most
problematic).
7
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CamilleriBrennan
(2003)34

IPAA (19)
Ileostomy (19)

Bodily pain
Energy/vitality

NR
NR

NR
NR

IBDQ (32-224)
(mean)
Bowel symptoms
Systemic symptoms
Emotional functioning
Social functioning

NR
54.4
NR
64.8

NR
63
NR
72.2

either instrument, although numerical
results were not reported.

<0.01
<0.01

SF-36 (0-100)
(median)
Overall health
Physical functioning
Role-physical
Role-emotional
Social functioning
Mental Health
Bodily pain
Energy/vitality

62
95
93.8
100
100
85
88.9
62.5

77
90
100
100
100
75
88.9
77

0.70
0.24
0.60
0.57
0.81
0.14
0.21
0.49

IBDQ (32-224)
(median)
Global score
Bowel symptoms
Systemic symptoms
Emotional functioning
Social functioning

85.4
81.7
80
84.7
95.8

80.7
80
83.3
80.6
91.7

0.56
0.32
0.25
0.76
0.56

There were no significant differences in
overall or domain specific measures of
HRQOL between the two groups.
Although a small sample size, the study
used matching to control for confounding
adding methodologic rigor to their
results. Body image was also explored
with a non-validated, self-developed
measure which did show inferior body
image among patients with ileostomies.

TTOT=Time Trade-Off Technique; DQO= Direct Questioning of Objectives; SIP = Sickness Impact Profile; NS = non-significant, NR = not recorded
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CHAPTER FOUR – A SYSTEMATIC REVIEW AND META-REGRESSION OF
OUTCOMES FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS
4.0 Introduction
Patients with ulcerative colitis who wish to avoid a permanent ileostomy have the
option to undergo a restorative proctocolectomy with an ileal pouch-anal anastomosis
(IPAA). This technique involves the formation of a reservoir using the small bowel
(ileum) and joining it to the anus to form a neo-rectum. Originally described by Parks and
Nicholls in 19781, the procedure has undergone many modifications and in its most
common form consists of a two-stage procedure where the colon and rectum is removed
and the pouch created, and protected with a diverting ileostomy that diverts the fecal
stream away from the pouch allowing it to heal2. Patients then undergo a closure of the
ileostomy at a second operation. It is important to note that this procedure does not
improve the control of ulcerative colitis, rather it is a procedure aimed at improving a
patient’s quality of life and day to day functioning through the avoidance of a stoma.
As explored in chapter three of this work, there is no conclusive evidence that it
universally leads to better health-related quality of life when compared to the
conventional proctocolectomy and ileostomy. Rather the decision to undergo a restorative
proctocolectomy should be made by the patient and be in line with their values and
expectations. In order to facilitate this decision, patients must be informed about the risks
of serious complications following the procedure. In order to provide estimates of these
complications for inclusion into our decision aid, a systematic review and meta-analysis
of serious outcomes following IPAA was conducted. One previous meta-analysis
published by Hueting et al in 2005 had several limitations3. They did not explore any
study quality items, no formal tests of heterogeneity were conducted, there were minimal
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efforts to explore heterogeneity among studies, no assessment of publication bias was
undertaken, and the review was dated as it only included studies published up to 2000.
We conducted an updated meta-analysis and took measures to explore and quantify
heterogeneity among studies.

4.1 Methods
Search Strategy
The details of the search strategy are presented in chapter two of this work, along
with the justification and listing of the specific inclusion criteria. Briefly, we included
studies of at least 100 patients that reported on outcomes of interest regardless of pouch
type, number of stages, and length of follow-up. All titles and abstracts were
independently reviewed by two reviewers, and any study that either reviewer deemed as
potentially eligible was selected for full text review. Study inclusion was then assessed
independently with any disagreement resolved by consensus. When conducting our
review, we followed the guidelines set out by the Meta-analysis of Observational Studies
in Epidemiology (MOOSE)4 and Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA)5 groups.
Data Extraction
All information was extracted independently by two reviewers with any
disagreements resolved by consensus using standardized, custom designed, dataabstraction sheets. Study characteristics including size; location; time period of patient
enrollment; length of follow-up; mean age; proportion with Crohn’s, FAP, or
indeterminate colitis; proportion with prior subtotal colectomy; proportion of stapled
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anastomosis; proportion with J-pouch configuration; and proportion with diverting loopileostomy were abstracted. Outcomes of interest included pouch failure (pouch excision
or permanent diverting ileostomy,), pelvic sepsis (pelvic abscess, anastomotic leakage, or
perineal wound infection), pouch-fistula (any fistula involving the pouch), stricture
(anastomotic stricture requiring dilatation), small bowel obstruction (requiring
laparotomy), and sexual dysfunction (erection disorder or dyspareunia). Functional
results were also extracted including mean number of bowel movements per day, mean
number of bowel movements at night, proportion with significant fecal incontinence,
fecal urgency (inability to defer defecation), proportion with daily pad use, and
proportion requiring daily anti-diarrheal medication use.
Quality Criteria
The justification for and rationale behind the selection of quality criteria is
discussed in depth in chapter two of this work, but a brief synopsis follows here.
Although many tools and scales exist for the assessment of quality criteria of
observational studies, no one tool can be recommended above others as there is no
empirical evidence linking specific observational study design elements to validity6, 7.
With that in mind, specific elements of study design reflective of quality were
investigated individually with regards to influence on outcome measures rather than using
summary scores of quality8. The study quality criteria examined included: whether or not
the patients represented a group of consecutive patients having surgery over a prespecified time period, whether the authors used clearly defined outcome criteria, whether
the study was retrospective or prospective, proportion loss to follow-up, and whether the
authors employed a standardized follow-up procedure.
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Meta-Analysis
Each study estimate of a given outcome was recorded and its 95% confidence
interval was determined using Wilson’s score method9. In order to combine the
proportions from individual studies, we converted the individual proportions into odds10,
and the odds were transformed into the log scale using equation 4.1:
ln(odds) = ln (no of patients having event/ no of patients not having event) (4.1)
This allowed us to generate a variance term which was used in the weighting of studies
for the meta-analysis (equation 4.2):

var ln(odds) = 1/no of patients having event + 1/ no of patients not having event10 (4.2).

Meta-analysis was then carried out using individual study proportions converted
to the ln(odds) scale according to the random-effects model of DerSimonian and Laird11,
accounting for both within-study variance and between-study variance. This model
assumes that the outcome measures of each study come from a random distribution of
outcomes, with the weighting of studies based on the reciprocal of the sum of between
study variance and within study variance. The statistical package, STATA version 10
(Stata inc, Texas, US, 2008) using the procedures meta and metan were used to metaanalyse the data as described by Sharp12. This procedure estimates the between-study
variance using the non-iterative weighted method of DerSimonian and Laird11. Pooled
results were converted back to the proportion scale and presented along with their 95%
confidence interval. In cases where the study had no events, a continuity correction factor
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was added (0.5) in order to generate an outcome measure for the meta-analysis as ln(0) is
not a real number. Adding a continuity correction is preferred over excluding studies with
zero events13. Each outcome was also graphically summarized using Forrest plots. The
possibility of publication bias was explored using funnel plots of the individual
outcomes, looking for asymmetry amongst the smaller trials. This was done assuming
smaller trials might be more apt to get published if they have “better” results, i.e. lower
rates of complications following IPAA.
Heterogeneity
Heterogeneity was statistically assessed for each outcome using the Cochran’s Q
chi-squared test which is calculated by adding together the squared deviations of each
study’s outcome from the overall pooled outcome, and then adjusting each deviation by
the study’s weight used in the meta-analysis14. This statistic, although widely used, is
often under-powered15, 16. In an effort to improve the test`s power, some author have
argued establishing a cut-off of 0.1 as the nominal level of significance for this test17, 18.
However, we maintained a value of 0.05 for this analysis as we had a large number of
studies which would improve its power. The degree of heterogeneity was also quantified
using the I2 statistic, which is the percentage of total variation across studies that is not
explained by chance19. The resulting value ranges from 0 (no heterogeneity) to increasing
proportions of non-chance related heterogeneity as the % I2 increases.
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Exploration of Heterogeneity
To explore the heterogeneity we conducted selective subgroup analyses on prespecified study characteristics, namely, 85% or greater proportion of pouches created
with J-configuration, studies with 100% diversion at the time of pouch creation, followup greater or equal to five years, and loss to follow-up of <10%. The most common
pouch configuration in the modern era is the J-pouch2, 20, 21 thus looking at studies that
include a majority of patients with this pouch configuration is most relevant to the
modern patient. While routine use of a diverting ileostomy has been linked to reduced
septic complications following IPAA and has been adopted by most surgeons22. Longer
follow-up has been linked to increased complication rates following IPAA as
complications such as pouch failure and pouchitis tend to occur over the long-term3, and
losses to follow-up have been empirically linked to differences in outcome measures in
meta-analyses of experimental literature23. Our other quality criteria, namely consecutive
patients (protection against selection bias), outcome criteria definition, and standardized
follow-up have not been shown in prior research to be linked with validity or outcome.
Each methodologic and study characteristic was systematically tested against the
outcome for its contribution to study heterogeneity using univariable and multivariable
meta-regression. Those factors that significantly contributed to heterogeneity amongst
studies were then considered for subgroup analysis provided there was a plausible clinical
or pathologic rationale. This last step was necessary to reduce concerns about multiple
testing and data dredging where associations may arise purely from chance alone24.
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Meta-Regression
Meta-regression involves exploring the linear association between study level
covariates and the pooled effect measure generated in the meta-analysis. It seeks to
determine how much of the heterogeneity is explained by variations in a single or a set of
given methodologic or study level factors10. It occurs at the study level with the outcome
being the meta-analyzed variable (here the ln(odds) of each outcome), and the covariates,
which include the study level factors (such as size, length of follow-up, etc).
Exploratory meta-regressions were undertaken to identify study level factors that
significantly contributed to the between-study variability. Study level factors explored
included methodologic criteria: consecutive patients, outcome definition, losses to
follow-up, study type (retrospective vs prospective), standardized follow-up, and length
of follow-up. The following study characteristics were also explored: mean age of
patients, mid-point year of patient cohort, proportion of patients with Crohn’s disease,
proportion of patients with FAP, proportion of patients with indeterminate colitis,
proportion undergoing diversion, proportion of stapled anastomoses, and proportion with
j-pouch configuration. For each study level factor, the significance of its association with
the outcome on the log scale and the proportion of outcome variability accounted for by
the factor were reported. For those that significantly contributed to outcome
heterogeneity, a plot of the study factor and the outcome on the log scale are presented
with the symbol representing each study, proportionally sized to the weight of the study.
Meta-regression was performed using the STATA command metareg, which carries out a
random-effects meta-regression and estimates the between study variance using the
iterative residual maximum likelihood method12. The use of a random-effects meta-
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regression is preferred as fixed-effects meta-regression would only be appropriate if all
the heterogeneity was explained by the covariates. This is generally not possible and the
residual heterogeneity must be acknowledged in the analysis24. In order to undertake a
random-effects meta-regression some estimate of residual between study variance must
be generated. Multiple methods exist, some based on empirical Bayesian estimates,
others on iterative restricted maximum likelihood estimates (REML). Iterative methods
are preferred as they do not require any subjective assumptions about prior
probabilities24. Only studies that reported on a given covariate (study factor) could
contribute to the meta-regression.

4.2 Results
4.2.1 Study Selection
Our searches resulted in 3920 abstracts and titles, with 411 full-text papers
retrieved for review and 67 studies ultimately met our inclusion criteria. There was good
agreement beyond chance between the two independent reviewers for study inclusion (k
= 0.87). The most common reason for exclusion were papers reporting on duplicate
cohorts of patients who had been treated at the same institution over a similar time period
(n=124). Other reasons for exclusion included studies with < 100 patients, review papers,
papers reporting on sub-groups only, studies reporting on outcomes not related to our
inclusion, and non-English language papers. Occasionally two papers from the same
center were included if they reported on different outcomes or reported on patients from
two non-overlapping time periods.
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4.2.2 Study Description
The 67 studies included 21,882 patients treated in 19 different countries who were
followed for a mean (SD) of 62.1 (34) months (range: 13-180 months). The studies
reported on patients operated on from 1977 to 2005, with specific time span of cohorts
differing from study to study (Table 4.1). The mean age at time of surgery was 34.9
years, ranging from 23.8 to 40 years (Table 4.2). Study size ranged from 100 to 1885
patients with an overall mean study size of 327 patients. Eighteen studies included
patients with Crohn’s disease, with proportions ranging from 0.16% to 24%, while 20
studies included patients with indeterminate colitis, ranging from 0.5% to 29.4%.
Patients with FAP were included in 33 studies with proportions ranging from 2.3% to
16%. The rate of proximal diversion (loop ileostomy) at the time of pouch creation varied
among studies with 28 studies reporting universal diversion with every patient, while the
rates of diversion varied between 20% and 99.3% among the other studies. The rates of
stapled-anastomosis also varied between 0% and 100%. The most common method of
pouch construction was the J-pouch configuration, with 17 studies reporting exclusively
on J-pouch patients. While the rates of J-pouch configuration varied between 3.1% and
99.5% among other studies.

4.2.3 Study Quality Assessment
Of the included studies, 25 (37% )were prospective, 42 (61%) included
consecutive patients, 30 (44%) studies used standardized follow-up, and 51 (76%) studies
used clearly defined outcomes to assess rates of complication, with 18 (27%) studies
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using clearly defined outcome criteria for all their reported outcomes. Fifty two studies
(77.6%) reported losses to follow-up; the average loss to follow-up was 7.5% (range 029%) and 36 studies reported less than 10% losses to follow-up.
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Table 4.1 Characteristics of Studies Reporting on Outcomes Following IPAA
Author
Fonkalsrud et
al25,1988
Nicholls et al26, 1989
Pescatori and
Mattana27, 1990
Wexner et al28, 1990
Becker et al29, 1991
Harms et al30, 1992
Fischer et al31, 1993
Mathey et al32, 1993
Sagar et al33, 1993
Atkinson et al34, 1994
Daude et al35, 1994
Hulten et al36,1994
Lewis et al37, 1994
Gorfine et al38, 1995
Hewett et al39, 1995
Sitzmann et al40, 1995
Stahlberg et al41, 1996
McCourtney and
Finlay42,1997
Romanos et al43, 1997
Breen et al44, 1998
Belliveau et al45, 1999
Fazio et al46, 1999
Neilly et al47, 1999
Tiainen et al48, 1999
Young et al49, 1999
Karlbom et al50, 2000
Keighley et al51, 2000
Mowschenson et
al52,2000
Simchuk and
Thirlby53, 2000
Sugerman et al54, 2000
Blumberg et al55, 2001
Heuschen et al56, 2001
Madiba and Bartolo57,
2001
Regimbeau et al58,
2001
Dayton et al59, 2002
Heuschen et al60, 2002
Lepisto et al61, 2002
MacLean et al62, 2002
Robb et al63, 2002
Rudolph et al64, 2002
de Oca et al65, 2003
Fazio et al66, 2003

Location

Consecutive
Patients
No

Type of Study

UCLA, US

Years of
Surgery
1977-1988

Retrospective

Outcomes
Defined
None

Standardized
Follow-up
No

St Marks, UK
Multicenter, Italy

1976-1986
1980-1989

Yes
No

Prospective
Retrospective

None
Some

No
No

Minnesota, US
Harvard, US
Wisconsin, US
Cincinnati, US
Multicenter, Swiss
Leeds, UK
Vancouver, Canada
Paris, France
Goteborg, Sweden
London, UK
New York, US
Brisbane, Australia
Baltimore, USA
Huddinge, Sweden
Glasgow, Scotland

1980-1988
1982-1990
1984-1991
NR
1980-1991
1980-1990
1984-1992
1983-1991
1982-1992
1983-1991
1992-1994
1981-1993
1987-1992
1980-1993
1988-1995

No
No
No
Yes
No
Yes
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes

Retrospective
Prospective
Retrospective
Retrospective
Retrospective
Prospective
Retrospective
Retrospective
Retrospective
Retrospective
Retrospective
Retrospective
Retrospective
Prospective
Retrospective

None
Some
Some
Some
Some
None
None
Some
Some
None
Some
None
Some
All
Some

No
Yes
No
No
No
No
No
Yes
No
Yes
No
No
Yes
Yes
Yes

Oxford, UK
Lahey Clinic, US
Montreal, Canada
Cleveland, US
Auckland, NZ
Tampere, Finland
Sydney, Australia
Uppsala, Sweden
Birmingham, UK
Boston, US

1983-1995
1980-1996
1981-1994
1986-1997
1982-1997
1985-1995
1984-1997
1983-1996
1983-1999
1989-1996

Yes
Yes
Yes
Yes
No
Yes
Yes
No
Yes
Yes

Retrospective
Prospective
Retrospective
Prospective
Retrospective
Retrospective
Retrospective
Retrospective
Prospective
Prospective

Some
All
None
Some
None
None
Some
Some
None
Some

Yes
Yes
No
Yes
Yes
No
No
Yes
No
No

Seattle, US

1987-1996

Yes

Retrospective

Some

Yes

Richmond, US
New Orleans, US
Heidlberg, Germany
Edinburgh, Scotland

1989-1999
1982-1995
1982-1997
1990-1999

Yes
No
Yes
No

Retrospective
Retrospective
Prospective
Prospective

Some
Some
All
All

Yes
No
Yes
Yes

Paris, France

1984-1998

Yes

Retrospective

None

Yes

Salt Lake City, US
Heidlberg, Germany
Helsinki, Finland
Toronto, Canada
Cincinnati, US
Louisville, US
Barcelona, Spain
Cleveland, US

1982-2001
1988-1999
1985-1999
1981-1999
1978-2001
1991-1999
1985-2000
1983-2001

Yes
Yes
No
Yes
No
Yes
No
Yes

Retrospective
Retrospective
Retrospective
Prospective
Retrospective
Prospective
Retrospective
Prospective

Some
Some
All
All
Some
Some
None
Some

Yes
Yes
Yes
Yes
No
No
No
Yes
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Fowler et al67, 2003
Michelassi et al68,
2003
Gosselink et al69, 2004
Hueting et al70,2004
Ikeuchi et al71, 2004
Marciniak et al72,
2004
Pishori et al73, 2004
Arai et al74, 2005
Brown et al75, 2005
Hallberg et al76, 2005
Ikeuchi et al77, 2005
Krausz et al78, 2005
Araki et al79, 2006
Bengtsson et al80,
2007
Berndtsson et al81,
2007
Das et al82, 2007
Hahnloser et al83,
2007
Nilubol et al84, 2007
Abdelrazeq et al85,
2008
Ferrante et al86, 2008
Fleshner et al87, 2008
Hoda et al88, 2008
Lovegrove89, 2008
Tulchinsky et al90,
2008
Rink et al91, 2009

Gloucester, UK
Chicago, US

1984-2001
1987-2002

Yes
Yes

Prospective
Prospective

Some
Some

No
Yes

Rotterdam,
Netherlands
Utrecht,
Netherlands
Hyogo, Japan
Poznan, Poland

1989-2001

Yes

Prospective

Some

Yes

1989-2000

No

Retrospective

Some

No

1984-2002
1984-2002

No
No

Retrospective
Retrospective

All
All

No
No

Florida, US
Yokohama, Japan
Toronto, Canada
Stockholm, Sweden
Hyogo, Japan
Haifa, Israel
Paris, France
Goteborg, Sweden

1988-2000
1993-2003
1982-2001
1990-1997
1999-2003
1984-2004
1998-2003
1984-2004

Yes
Yes
Yes
No
No
Yes
Yes
No

Retrospective
Retrospective
Prospective
Prospective
Retrospective
Retrospective
Prospective
Retrospective

Some
Some
Some
All
Some
Some
None
All

No
No
Yes
Yes
No
No
No
No

Goteborg, Sweden

1982-1995

No

Retrospective

All

No

St Marks, UK
Mayo Clinic, US

1978-2006
1981-2000

No
Yes

Retrospective
Prospective

All
Some

No
Yes

New York, US
York, UK

1988-1999
1988-2003

No
Yes

Prospective
Retrospective

All
All

Yes
Yes

Leuven, Belgium
Los Angeles, US
Oregon, US
Sheffield, UK
Tel-Aviv, Israel

1990-2004
NR
1993-2003
1987-2006
1986-2005

Yes
Yes
No
No
No

Retrospective
Prospective
Retrospective
Prospective
Prospective

All
All
All
None
All

Yes
No
No
No
No

Guttenberg, Germany

1990-2002

Yes

Retrospective

Some

Yes
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Table 4.2 Characteristics of Patients in IPAA Studies
Author
Fonkalsrud et
al25,1988
Nicholls et al26, 1989
Pescatori and
Mattana27, 1990
Wexner et al28, 1990
Becker et al29, 1991
Harms et al30, 1992
Fischer et al31, 1993
Mathey et al32, 1993
Sagar et al33, 1993
Atkinson et al34, 1994
Daude et al35, 1994
Hulten et al36,1994
Lewis et al37, 1994
Gorfine et al38, 1995
Hewett et al39, 1995
Sitzmann et al40, 1995
Stahlberg et al41, 1996
McCourtney and
Finlay42,1997
Romanos et al43, 1997
Breen et al44, 1998
Belliveau et al45, 1999
Fazio et al46, 1999
Neilly et al47, 1999
Tiainen et al48, 1999
Young et al49, 1999
Karlbom et al50, 2000
Keighley et al51, 2000
Mowschenson et
al52,2000
Simchuk and
Thirlby53, 2000

N

%
Crohn’s
0

%
FAP
9.3

%
IC
2.7

%
Diversion
100

% Priorsubtotal
NR

% Stapled

% J-pouch

172

Patient Mean
Age (Range) y
23.8(7-58)

87.5

Length of
Follow-up
NR

Loss to
Follow-up (%)
NR

44.8

116
207

30 (14-52)
34 (8-67)

0
0

0
31.4

0
0

75.8
99.3

62.5
30

0
24.2

12.9
63.3

41
13.4

1.3
NR

180
250
109
200
157
103
158
156
307
115
143
126
105
149
103

31
35 (11-67)
32.4 (11-67)
NR
33.5 (10-65)
34 (14-64)
34 (19-59)
35
NR
35
34
NR
NR
34* (8-64)
31 (12-77)

0
0
0
0
0
0
0
0
0
1.7
0.7
0
0
0
0

6.1
16
17.4
0
19
10.7
0
0
0
6.1
9.8
0
17.1
0
8.7

0
0
0
0
0
0
0
0
0
0
0.7
0
8.5
0
0

100
100
100
100
100
100
100
100
100
67.8
48.3
100
100
100
73.8

12.2
NR
98.1
NR
56.7
NR
NR
35
NR
35.6
46.8
NR
29.5
NR
26.2

0
100
0
0
12.1
66.9
100
0
NR
0
0
0
0
100
100

1.1
100
0
3.5
82.8
13.6
100
NR
10.4
100
51.4
100
100
100

60
NR
33.6
NR
37
NR
NR
29
66
34
18
51
37.2
54*
31

1.1
0
0
2.5
26
6.3
NR
0
17
0
6.3
15
0
0
3.9

200
628
239
977
187
136
100
182
202
133

33 (6-67)
NR
34
37
32 (14-63)
35.5(19-63)
35* (5-68)
32 (16-68)
35.6 (13-77)
34.1

0
0.3
4.1
3.5
3.9
0
0
0
0
0

3.5
8.3
4.6
3.8
9.4
0
20
0
0
2.3

6.5
7.5
0
12.6
3.4
0
5
0
0
0

69.5
100
100
100
51.7
100
100
70.8
100
30.8

NR
NR
36.8
NR
NR
47.1
42
56
57.4
NR

73.5
NR
32.8
100
74.1
2.1
50
45.8
90.6
100

71
NR
32.8
80.1
65.2
100
100
45.8
90.6
100

27*
56
NR
60
73.2
NR
68
29*
91.3
NR

2.0
3.7
NR
15
7.9
NR
0
8
0
16.5

114

39 (16-72)

2.6

11.4

0

100

NR

0

100

38

2.6
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Sugerman et al54, 2000
Blumberg et al55, 2001
Heuschen et al56, 2001
Madiba and Bartolo57,
2001
Regimbeau et al58,
2001
Dayton et al59, 2002
Heuschen et al60, 2002
Lepisto et al61, 2002
MacLean et al62, 2002
Robb et al63, 2002
Rudolph et al64, 2002
de Oca et al65, 2003
Fazio et al66, 2003
Fowler et al67, 2003
Michelassi et al68,
2003
Gosselink et al69, 2004
Hueting et al70,2004
Ikeuchi et al71, 2004
Marciniak et al72, 2004
Pishori et al73, 2004
Arai et al74, 2005
Brown et al75, 2005
Hallberg et al76, 2005
Ikeuchi et al77, 2005
Krausz et al78, 2005
Araki et al79, 2006
Bengtsson et al80,
2007
Berndtsson et al81,
2007
Das et al82, 2007
Hahnloser et al83, 2007
Nilubol et al84, 2007
Abdelrazeq et al85,
2008
Ferrante et al86, 2008

192
145
210
139

38 (7-70)
34 (14-70)
34.4
38.2 (13-74)

2.6
0
0
0

4.2
23.4
0
0

0.5
0
0
0

0
83.4
100
100

88.5
15.2
NR
25.2

100
NR
100
0

100
35.9
100
97.1

61.2
NR
51
60

11
NR
11.5
NR
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36 (16-72)

24.4

27.9

0

100

NR

0

100

60

26

565
494
486
1178
379
120
100
1965
106
391

37
34.2*
NR
40.7
35.9 (5-84)
38 (7-72)
32 (15-63)
37.5
40(13-77)
33.7 (12-66)

0
0
0
0
1.6
11.7
0
3.8
3.8
0

0
0
7.4
5.6
10.3
0
0
7.3
10.4
0

0
0
0
0
0
29.2
1
27.9
1.9
3.3

100
91
32.7
66
100
76.7
100
86.7
41.3
65

14
29.8
15
50
NR
5.8
78
35.1
NR
NR

100
100
7.8
NR
10.8
NR
NR
85.3
0
29.9

100
100
NR
NR
10.8
NR
NR
87.4
0
100

78.5
56.7*
NR
104.4
103.3
47
83
49.2
NR
24*

11
3.2
NR
8.1
14.2
1.2
NR
24.2
1
9.7

127
111
521
110
303
296
1135
100
242
174
123
620

35* (14-67)
35.4
NR
NR
NR
33.8
34
32*(12-71)
33*(15-69)
NR
37.5(10-69)
35.5 (13-75)

3.9
0
0
0
1.6
0
0
0
0
0
0
1.8

0
0
0
34.5
0
0
0
0
0
16.1
0
4.7

0
0
0
0
4.3
0
0
0
0
0
5.7
0

21.3
NR
NR
NR
97
55.4
64.7
71
38
87.4
66.7
NR

73.2
NR
NR
NR
36.3
2.4
57.2
NR
NR
NR
41.5
NR

0
NR
5.7
NR
100
96.3
71.2
100
0
46
0
NR

3.1
NR
100
NR
100
100
81.6
100
100
63.2
100
NR

68*
42*
NR
21.6
40
52.6
98
48*
NR
64.8
NR
168

0
18.9
NR
NR
NR
0
0
10
NR
24.7
0
6.9

399

34 (13-74)

0

0

0

NR

NR

NR

33.6

180*

7.3

1822
1885
138
198

NR
34 (12-68)
36.1
38.3 (14-64)

NR
0
1.4
0

NR
0
7.2
0

NR
0
5.8
0

NR
98.4
100
68.2

NR
NR
NR
NR

NR
NR
0
100

NR
96.8
87.7
100

120*
129.6
64.8
64

NR
0
6.5
3

173

39

0

0

1.2

66.5

18.5

95.4

97.7

78

6

87
Fleshner et al87, 2008
Hoda et al88, 2008
Lovegrove et al92,
2008
Tulchinsky et al90,
2008
Rink et al91, 2009

238
167
199

38 (8-81)
36
37.6

0
0
0.5

0
0
5

29.4
0
8.5

100
91.5
20.1

NR
34.7
43.5

NR
NR
99

100
NR
99.5

47
NR
NR

0
29.5
NR

120

37 (13-75)

0

0

0

86.7

21.6

NR

NR

65

16.1

131

33 (12-70)

0

0

0

84

23.7

0

100

85

3.1
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4.2.4 Complications
Pouch Failure
Forty-six studies totaling 15,793 patients reported on pouch failure with
individual study estimates ranging from 1.0% to 16.7%25-28, 32, 34-45, 47, 49-55, 58, 59, 61, 64, 66-69,
73-76, 78, 80-83, 86, 89, 91, 93

. The pooled estimate including all studies was 5.5% (95% CI,

4.7%-6.5%) with significant heterogeneity p=<0.001 and I2 at 77.3% (Table 4.3, page
111). Figure 4.1 graphically summarizes each study’s estimate, 95% confidence interval,
and the pooled estimate. Studies with ≥85% J-pouch and studies with ≥85% diverting
ileostomy had lower rates of pouch failure when compared to the overall rate, 3.8% (95%
CI, 2.9%-5.1%) and 4.6% ( 95% CI, 3.6%-5.9%) respectively (Table 4.4, page 111).
Studies with at least 5 years of follow-up had higher rates of pouch failure at 6.3% (95%
CI, 5.1%-7.7%) when compared to the overall rate. Restricting the analysis to studies
with less than 10% loss to follow-up had little effect on the summary estimate (Table
4.4). Despite division into subgroups, heterogeneity remained significant for all groups.
At the study level, only the length of follow-up was associated with a statistically
significant increase in the rate of pouch failure in both univariable and multivariable
meta-regression, accounting for 16.83% of between study heterogeneity (p = 0.05, Figure
4.2). Funnel plot of the outcome on the log scale plotted against study size reveals
evidence of publication bias with few small studies being published with higher rates of
pouch failure (Figure 4.3).
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Figure 4.1 Forrest plot of studies reporting on rates of pouch failure. Point estimates are
provided along with 95% confidence intervals for each study and the pooled estimate.
Studies are arranged in increasing order of size.
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Figure 4.2 Meta-regression of length of follow-up on rate of pouch failure (ln(odds)).
Studies with longer follow-up had higher rates of pouch failure, accounting for 16.6% of
between-study variability (p = 0.05). The area of the circle is proportional to the number
of patients in each study.
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Figure 4.3 Funnel plot showing rate of pouch failure (ln(odds)) against study size. Lack
of studies in bottom right hand corner indicates a lack of small studies being published
with higher rates of pouch failure.
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Pelvic Sepsis
Forty-four studies totaling 13,252 patients reported on pelvic sepsis with
individual study estimates ranging from 0-26%25-28, 30-32, 34-40, 42-45, 47-51, 53-55, 58-60, 66-70, 73-79,
83, 86, 89

. The pooled estimate including all studies was 8.0% (95% CI, 6.8%-9.4%) with

significant heterogeneity p = <0.001 and I2 at 84.8% (Table 4.3). Figure 4.4 graphically
summarizes each study`s point estimate, its 95% confidence interval, and the pooled
estimate. Studies with ≥85% use of diverting ileostomy had slightly lower rates of pelvic
sepsis when compared to the overall rate 6.9% (95% CI, 5.7%-8.7%). While studies with
> 5 years follow-up, and <10% lost to follow-up had slightly higher rates of pelvic sepsis,
9.1% (95% CI, 6.9-12.2) and 9.0% (95% CI, 7.2%-11.1%) respectively. Restricting the
analysis to studies with ≥85% J-pouch had little effect on the summary estimate (Table
4.4). At the study level, only study type was associated with a change in rate of pelvic
sepsis with a significant increase in the rate of pelvic sepsis among prospective studies in
both univariable and multivariable meta-regression, accounting for 25.09% of between
study variability (p = 0.005, Figure 4.5). Prospective studies (13 studies, n = 7,150)
reported higher rates of pelvic sepsis when compared to the overall rate, 11.4% (95%CI,
9.3%-14.1%). Funnel plot of the outcome on the log scale plotted against study size
reveals evidence of publication bias with few small studies being published with higher
rates of pelvic sepsis (Figure 4.6).
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Figure 4.4 Forrest plot of studies reporting on rates of pelvic sepsis. Point estimates are
provided along with 95% confidence intervals for each study and the pooled estimate.
Studies are arranged in increasing order of size.
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Figure 4.5 Meta-regression of study type (0 = retrospective, 1 = prospective) on rate of
pelvic sepsis (ln(odds)). Prospective studies reported higher rates of pelvic sepsis,
accounting for 25.09% of between study variability (p = 0.005). The area of the circle is
proportional to the number of patients in each study.
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Figure 4.6 Funnel plot showing rate of pelvic sepsis (ln(odds)) against study size. Lack
of studies in bottom right hand corner indicates a lack of small studies being published
with higher rates of pelvic sepsis.
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Pouch Fistula
Thirty-six studies totaling 12,155 patients reported on pouch fistula with
individual study estimates ranging from 1.6-15.8%25, 26, 28, 32, 34-36, 39, 43-45, 47, 48, 51, 53-55, 58-61,
64, 66-70, 73-75, 77, 78, 83, 86, 89-91, 93

. The pooled estimate including all studies was 5.1% (95%

CI, 4.1%-6.5%) with significant heterogeneity p = <0.001 and I2 at 88.5% (Table 4.3).
Figure 4.7 graphically summarizes each study`s point estimate, its 95% confidence
interval, and the pooled estimate. Studies with at least 5 years of follow-up had higher
rates of pouch fistula at 6.5% (95% CI, 3.7%-8.9%). Restricting the analysis to studies
with ≥85% J-pouch, ≥85% diverting ileostomy, or < 10% follow-up had little effect on
the summary estimate (Table 4.4). At the study level, only outcome criteria definition
was associated with a change in rate of pouch fistula. In both univariable and
multivariable meta-regression, studies using clearly defined outcome criteria reported
higher rates of pouch fistula, accounting for 24.8% of between study variability (p =
0.003, Figure 4.8). Studies (9, n =2,264) using clearly defined outcome criteria reported
higher rates of pouch fistula compared to the overall estimate 9.4% (95% CI,7.2%12.3%). Funnel plot of the outcome on the log scale plotted against study size reveals
evidence of publication bias with few small studies being published with higher rates of
pouch fistula (Figure 4.9).
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Figure 4.7 Forrest plot of studies reporting on rates of pouch fistula. Point estimates are
provided along with 95% confidence intervals for each study and the pooled estimate.
Studies are arranged in increasing order of size.
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Figure 4.8 Meta-regression of outcome definition (0 =not defined, 1 = clearly defined)
on rate of pouch fistula (ln(odds)). Studies with clearly defined outcomes reported higher
rates of pouch fistula, accounting for 29.1% of between study variability (p = 0.003). The
area of the circle is proportional to the number of patients in each study.
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Figure 4.9 Funnel plot showing rate of pouch fistula (ln(odds)) against study size. Lack
of studies in bottom right hand corner indicates a lack of small studies being published
with higher rates of pouch fistula.
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Anastomotic Stricture
Twenty nine studies totaling 7,533 patients reported on anastomotic stricture with
individual study estimates ranging from 1.6-33%25, 30, 32, 35-37, 40, 42-45, 47, 49-51, 53, 58, 59, 64, 66-69,
73, 76, 78, 79, 89, 93

. The pooled estimate including all studies was 9.1% (95% CI, 6.6%-

11.5%) with significant heterogeneity p = <0.001 and I2 at 89.7% (Table 4.3). Figure 4.10
graphically summarizes each study`s point estimate, its 95% confidence interval, and the
pooled estimate. Restricting the analysis to studies with ≥85% J-pouch, ≥85% diverting
ileostomy, at least 5 years of follow-up, or < 10% follow-up had little effect on the rate of
anastomotic stricture (Table 4.4). At the study level, only outcome criteria definition was
associated with a change in rate of anastomotic stricture. In both univariable and
multivariable meta-regression, studies using clearly defined outcome criteria reported
higher rates of anastomotic stricture, accounting for 19.4% of between study variability
(p = 0.014, Figure 4.11). Studies (13, n =2,568) using clearly defined outcome criteria
reported higher rates of pouch fistula compared to the overall estimate 12.6% (95% CI,
9.5%-16.7%). Funnel plot of the outcome on the log scale plotted against study size
reveals evidence of publication bias with few small studies being published with higher
rates of anastomotic stricture (Figure 4.12).
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Figure 4.10 Forrest plot of studies reporting on rates of anastomotic stricture. Point
estimates are provided along with 95% confidence intervals for each study and the pooled
estimate. Studies are arranged in increasing order of size.

-2
-4

-3

ln(odds)

-1

0

99

0

.2

.4
.6
outcome definition

.8

1

Figure 4.11 Meta-regression of outcome definition (0 =not defined, 1 = clearly defined)
on rate of anastomotic stricture (ln(odds)). Studies with clearly defined outcomes
reported higher rates of stricture, accounting for 19.4% of between study variability (p =
0.014). The area of the circle is proportional to the number of patients in each study.
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Figure 4.12Funnel plot showing rate of anastomotic stricture (ln(odds)) against study
size. Lack of studies in bottom right hand corner indicates a lack of small studies being
published with higher rates of stricture.
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Pouchitis
Fifty studies totaling 13,003 patients reported on rates of pouchitis with individual
study estimates ranging from 2-60%25, 27, 28, 30-32, 35-37, 39-43, 45, 47-59, 61, 63, 64, 66, 67, 69-74, 78, 83-86,
88-91, 93, 94

. The pooled estimate including all studies was 22.0% (95% CI, 19.4%-26.5%)

with significant heterogeneity p = <0.001 and I2 at 95.3% (Table 4.3). Figure 4.13
graphically summarizes each study estimate, its 95% confidence interval, and the pooled
estimate. Studies with at least 5 years of follow-up had higher rates of pouchitis at 28.1%
(95% CI, 22.3-34.6%). Restricting the analysis to studies with ≥85% J-pouch, ≥85%
diverting ileostomy, or < 10% follow-up had little effect on the summary estimate (Table
4.4). At the study level, both outcome criteria definition and length of follow-up were
associated with a change in the rate of pouchitis. In both univariable and multivariable
meta-regression, studies using clearly defined outcome criteria reported higher rates of
pouchitis, accounting for 17.22% of between study variability (p = 0.002, Figure 4.14),
while the association with length of follow-up was only seen in univariable analysis.
Studies (26, n =8,360) using clearly defined outcome criteria reported higher rates of
pouchitis compared to the overall estimate, 28.7% (95% CI, 23.6%-34.5%). Funnel plot
of the outcome on the log scale plotted against study size reveals evidence of publication
bias with few small studies being published with higher rates of pouchitis (Figure 4.15).
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Figure 4.13 Forrest plot of studies reporting on rates of pouchitis. Point estimates are
provided along with 95% confidence intervals for each study and the pooled estimate.
Studies are arranged in increasing order of size.
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Figure 4.14 Meta-regression of outcome definition (0 =not defined, 1 = clearly defined)
on rate of pouchitis (ln(odds)). Studies with clearly defined outcomes reported higher
rates of pouchitis, accounting for 17.22% of between study variability (p = 0.002). The
area of the circle is proportional to the number of patients in each study.
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Figure 4.15 Funnel plot showing rate of pouchitis (ln(odds)) against study size. Lack of
studies in bottom right hand corner indicates a lack of small studies being published with
higher rates of pouchitis.
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Small Bowel Obstruction
Thirty-five studies totaling 11,069 patients reported on the rates of small bowel
obstruction (SBO), with individual study estimates ranging between 1% and 52%25, 26, 28,
30-32, 36, 38-40, 43, 45, 47-49, 52-55, 58, 59, 62, 64, 66-69, 73, 74, 77, 78, 83, 86, 89, 93

. The pooled estimate

including all studies was 11.8% (95% CI, 9.0%-15.3%) with significant heterogeneity p =
<0.001 and I2 at 96.6% (Table 4.3). Figure 4.16 graphically summarizes each study
estimate, its 95% confidence interval, and the pooled estimate. Studies with at least 5
years of follow-up, and studies with less than 10% loss to follow-up had higher rates of
small bowel obstruction at 13.2% (95% CI, 8.3%-20.1%) and 14% (95%CI, 9.8%-19.5%)
respectively. Restricting the analysis to studies with ≥85% J-pouch, or ≥85% diverting
ileostomy had little effect on the summary estimate (Table 4.4). In both univariable and
multivariable meta-regression, studies using clearly defined outcome criteria reported
higher rates of small bowel obstruction, accounting for 10.4% of between study
variability (p = 0.04, Figure 4.17). Studies (5, n =1,054) using clearly defined outcome
criteria reported higher rates of small bowel obstruction compared to the overall estimate,
22.5% (95% CI, 19.3%-26.5%). Funnel plot of the rate of small bowel obstruction on the
log scale plotted against study size reveals evidence of publication bias with fewer small
studies being published with higher rates of small bowel obstruction (Figure 4.18).
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Figure 4.16 Forrest plot of studies reporting on rates of small bowel obstruction. Point
estimates are provided along with 95% confidence intervals for each study and the pooled
estimate. Studies are arranged in increasing order of size.
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Figure 4.17 Meta-regression of outcome definition (0 =not defined, 1 = clearly defined)
on rate of small bowel obstruction (ln(odds)). Studies with clearly defined outcomes
reported higher rates of small bowel obstruction, accounting for 10.40% of between study
variability (p = 0.041). The area of the circle is proportional to the number of patients in
each study.
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Figure 4.18 Funnel plot showing rate of small bowel obstruction (ln(odds)) against study
size. Lack of studies in bottom right hand corner indicates a lack of small studies being
published with higher rates of small bowel obstruction.

106
Sexual Dysfunction
Nineteen studies totaling 5,003 patients reported on the rates of sexual
dysfunction, with individual study estimates ranging between 0% and 13.6%25-27, 29, 31, 33,
35, 36, 39, 43, 47, 52, 54, 58, 78, 83, 89, 93

. The pooled estimate including all studies was 4.6% (95%

CI, 3.0%-6.8%) with significant heterogeneity p = <0.001 and I2 at 95.1% (Table 4.3).
Figure 4.19 graphically summarizes each study estimate, its 95% confidence interval, and
the pooled estimate. Studies with at least 5 years of follow-up had higher rates of sexual
dysfunction at 5.9% (95% CI, 3.5%-9.8%), while studies with ≥85% J-pouch had lower
rates of sexual dysfunction when compared to the overall rate, 3.1% (95% CI, 1,2%9.7%). Restricting the analysis to studies with ≥85% diverting ileostomy or loss to
follow-up of <10% had little effect on the summary estimate (Table 4.4). Meta-regression
did not reveal any association between study level factors and rate of sexual dysfunction.
Funnel plot of the rate of sexual dysfunction on the log scale plotted against study size
reveals evidence of publication bias with few small studies being published with higher
rates of sexual dysfunction (Figure 4.20).
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%

Figure 4.19 Forrest plot of studies reporting on rates of sexual dysfunction. Point
estimates are provided along with 95% confidence intervals for each study and the pooled
estimate. Studies are arranged in increasing order of size.
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Figure 4.20 Funnel plot showing rate of sexual dysfunction (ln(odds)) against study size.
Lack of studies in bottom right hand corner indicates a lack of small studies being
published with higher rates of sexual dysfunction.
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Table 4.3 Results of Meta-Analysis of Complication Rates Following IPAA
Complication
Pouch Failure
Pelvic Sepsis
Pouch fistula
Stricture
Pouchitis
SBO
Sexual
dysfunction

Number
of Studies
46
44
36
29
50
35
19

Number of
Patients
15,793
13,252
12,155
7,533
13,003
11,069
5,003

Pooled %

95% CI

5.5
8.0
5.1
9.1
22.0
11.8
4.6

4.7-6.5
6.8-9.4
4.1-6.5
6.5-11.5
19.4-26.5
9.0-15.3
3.0-6.8

Heterogeneity
I2(%)
p
77.3
<0.001
84.8
<0.001
88.5
<0.001
89.7
<0.001
95.3
<0.01
96.6
<0.001
95.1
<0.001

SBO small bowel obstruction

Table 4.4 Subgroup Meta-Analysis of Complications Following IPAA
Sub-Group
≥85% J-pouch
Pouch failure
Pelvic sepsis
Pouch fistula
Anastomotic stricture
Pouchitis
SBO
Sexual dysfunction
≥85% Diverting ileostomy
Pouch failure
Pelvic sepsis
Pouch fistula
Anastomotic stricture
Pouchitis
SBO
Sexual dysfunction
Follow-up ≥ 5yrs
Pouch failure
Pelvic sepsis
Pouch fistula
Anastomotic stricture
Pouchitis
SBO
Sexual dysfunction
< 10% lost to follow-up
Pouch failure
Pelvic sepsis
Pouch fistula
Anastomotic stricture
Pouchitis
SBO
Sexual dysfunction

No.
Studies

No.
of Patients

Pooled %

95% CI

Heterogeneity
I2
p

14
16
13
10
18
13
5

6,535
7,425
6,815
4,194
7,954
6,651
2,581

3.8
7.5
4.5
9.1
21.3
12.0
3.1

73.2
91.7
73.6
93.4
92.5
98.2
89.8

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

22
24
20
17
30
19
12

8,350
8,985
8,073
5,581
9,168
7,037
3,864

4.6
6.9
4.4
8.9
24.2
11.3
5.3

2.9-5.1
5.6-9.9
3.5-5.8
6.1-13.8
16.2-27.4
7.3-18.9
1.2-9.7
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3.6-5.9
5.7-8.7
3.0-6.4
6.6-11.9
20.0-29.0
7.5-16.8
3.4-8.3

80.8
86.5
83.3
91.0
95.8
97.5
87.9

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

17
12
13
20
18
13
7

8,290
5,377
5,338
5,659
5,349
5,123
3,017

6.3
9.1
6.5
9.5
28.1
13.2
5.9

5.1-7.7
6.9-12.2
3.7-8.9
7.3-12.4
22.3-34.6
8.3-20.1
3.5-9.8

76.8
89.5
92.7
89.4
93.3
97.4
88.7

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

26
23
17
17
24
18
8

8,049
7,299
6,449
3,128
5,543
5,663
3,097

5.7
9.0
5.8
9.4
22.4
14.0
4.0

4.6-7.1
7.2-11.1
4.0-8.3
6.8-12.7
17.4-28.2
9.8-19.5
2.3-8.0

79.4
86.0
88.5
89.7
95.3
96.4
90.3

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
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4.2.5 Functional Results
Fecal Incontinence
Thirty studies totaling 9,284 patients reported on the rates of fecal incontinence,
with individual study estimates ranging between 3% and 45%26-32, 35, 38-40, 43, 44, 46, 47, 50, 52,
54, 64, 68-70, 74-76, 81, 83, 86, 89, 93

. The pooled estimate including all studies was 13.2% (95% CI,

9.9%-17.3%) with significant heterogeneity p = <0.001 and I2 at 96.0% (Table 4.5).
Figure 4.21 graphically summarizes each study’s estimate, its 95% confidence interval,
and the pooled estimate. Studies with at least 5 years of follow-up had higher rates of
fecal incontinence at 15.9% (95% CI, 9.6%-25.4%), while studies with ≥85% J-pouch
had lower rates, 9.1% (95%CI, 3.3%-24.5%). Restricting the analysis to studies ≥85%
diverting ileostomy, or <10% follow-up had little effect on the summary estimate (Table
4.6). At the study level, outcome criteria definition (p = 0.009, Figure 4.22) and length of
follow-up (p = 0.009, Figure 4.23) were associated with an increased rate of fecal
incontinence, accounting for 22.59% and 19.91% of between study variability; while
proportion of J-pouch (p = 0.009, Figure 4.24) was associated with a decrease rate of
fecal incontinence, accounting for 22.06% of variability. These associations were seen at
the univariable level, but lost their significance when subjected to multivariable metaregression. Studies (9, n =4,354) using clearly defined outcome criteria reported higher
rates of fecal incontinence compared to the overall estimate, 21.3% (95% CI, 13.6%31.8%). Funnel plot of the rate of fecal incontinence on the log scale plotted against study
size reveals evidence of publication bias with few small studies being published with
higher rates of fecal incontinence (Figure 4.25).
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Figure 4.21 Forrest plot of studies reporting on rates of fecal incontinence. Point
estimates are provided along with 95% confidence intervals for each study and the pooled
estimate. Studies are arranged in increasing order of size.
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Figure 4.22 Meta-regression of outcome definition (0 =not defined, 1 = clearly defined)
on rate of fecal incontinence (ln(odds)). Studies with clearly defined outcomes reported
higher rates of fecal incontinence, accounting for 22.59% of between study variability (p
= 0.009). The area of the circle is proportional to the number of patients in each study.
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Figure 4.23 Meta-regression of length of follow-up (months) on rate of fecal
incontinence (ln(odds)). Studies with longer follow-up reported higher rates of fecal
incontinence, accounting for 19.91% of between study variability (p = 0.02). The area of
the circle is proportional to the number of patients in each study
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Figure 4.24 Meta-regression of proportion of patients with J-pouch on rate of fecal
incontinence (ln(odds)). Studies with a higher proportion of J-pouch reported lower rates
of fecal incontinence, accounting for 22.06% of between study variability (p = 0.04). The
area of the circle is proportional to the number of patients in each study.

.2
.3
.4
.5

s.e. of lnodds

.1

0

Funnel plot with pseudo 95% confidence limits

-3

-2
-1
Rate of fecal incontinence (lnodds)

0

Figure 4.25 Funnel plot showing rate of fecal incontinence (ln(odds)) against study size.
Lack of studies in bottom right hand corner indicates a lack of small studies being
published with higher rates of fecal incontinence.
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Fecal Urgency
Fourteen studies totaling 3,434 patients reported on the rates of fecal urgency,
with individual study estimates ranging between 2.5-25%32, 33, 35, 43, 47, 50, 52, 58, 70, 75, 81, 86, 89,
91

. The pooled estimate including all studies was 8.8% (95% CI, 6.4%-12.2%) with

significant heterogeneity p = <0.001 and I2 at 88.2% (Table 4.5). Figure 4.26 graphically
summarizes each study estimate, its 95% confidence interval, and the pooled estimate.
Studies with <10% loss to follow-up had higher rates of fecal urgency at 11.5% (95% CI,
6.4%-12.2%), while studies with ≥85% J-pouch had lower rates, 3.9% (95%CI, 2.4%6.4%). Restricting the analysis to studies ≥85% diverting ileostomy, or at least 5 years of
follow-up had little effect on the summary estimate (Table 4.6). At the study level,
proportion of J-pouch was associated with a decrease rate of urgency, accounting for
74.65%% of between study variability (p = 0.008, Figure 4.27). Funnel plot of the rate of
urgency on the log scale plotted against study size reveals evidence of publication bias
with few small studies being published with higher rates of urgency (Figure 4.28).
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Figure 4.26 Forrest plot of studies reporting on rates of fecal urgency. Point estimates
are provided along with 95% confidence intervals for each study and the pooled estimate.
Studies are arranged in increasing order of size.
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Figure 4.27 Meta-regression of proportion of patients with J-pouch on rate of fecal
urgency (ln(odds)). Studies with a higher proportion of J-pouch reported lower rates of
fecal urgency, accounting for 74.65% of between study variability (p = 0.008). The area
of the circle is proportional to the number of patients in each study.
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Figure 4.28 Funnel plot showing rate of fecal urgency (ln(odds)) against study size. Lack
of studies in bottom right hand corner indicates a lack of small studies being published
with higher rates of fecal urgency.

116
Pad Use
Twenty studies totaling 7,341 patients reported on the rates of pad use, with
individual study estimates ranging between 2.1%-39%28, 31-33, 37, 39, 44, 46, 50, 52, 54, 58, 70, 75, 78,
81, 83, 86, 89, 93

. The pooled estimate including all studies was 13.7% (95% CI, 10.6%-

18.1%) with significant heterogeneity p = <0.001 and I2 at 94.8% (Table 4.5). Figure 4.29
graphically summarizes each study estimate, its 95% confidence interval, and the pooled
estimate. Studies with ≥85% J-pouch had lower rates of pad use, 6.0% (95% CI, 2.1%16.5%). Restricting the analysis to studies with at least 5 years of follow-up had little
effect on the summary estimate, while studies with <10% lost to follow-up had slightly
higher rate of pad use, as did studies with ≥85% diverting ileostomy (Table 4.6). At the
study level, proportion of J-pouch (p = 0.02, Figure 4.30) was associated with a decrease
rate of pad use, accounting for 23.56% of between study variability. Funnel plot of the
rate of pad use on the log scale plotted against study size reveals evidence of publication
bias with few small studies being published with higher rates of pad use (Figure 4.31).
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Figure 4.29 Forrest plot of studies reporting on rates of pad use. Point estimates are
provided along with 95% confidence intervals for each study and the pooled estimate.
Studies are arranged in increasing order of size.
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Figure 4.30 Meta-regression of proportion of patients with J-pouch on rate of pad use
(ln(odds)). Studies with a higher proportion of J-pouch reported lower rates of pad use,
accounting for 23.56% of between study variability (p = 0.02). The area of the circle is
proportional to the number of patients in each study.

.2
.3
.4
.5

s.e. of lnodds

.1

0

Funnel plot with pseudo 95% confidence limits

-4

-3

-2
rate of pad use (lnodds)

-1

0

Figure 4.31 Funnel plot showing rate of pad use (ln(odds)) against study size. Lack of
studies in bottom right hand corner indicates a lack of small studies being published with
higher rates of pad use.
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Anti-Diarrheal Medication Use

Twenty-four studies totaling 6,153 patients reported on the rates of anti-diarrheal
(AD) medication use, with individual study estimates ranging between 12.6%-60%26-30, 32,
33, 37, 39, 43, 44, 47, 50, 52, 58, 64, 70, 78, 81, 83, 86, 89, 91, 93

. The pooled estimate including all studies

was 32.9% (95% CI, 27.3%-39.4%) with significant heterogeneity p = <0.001 and I2 at
95.1% (Table 4.5). Figure 4.32 graphically summarizes each study estimate, its 95%
confidence interval, and the pooled estimate. There was little difference between the rates
of AD medication use among subgroups (Table 4.6). Similarly, no study level factors
were significantly associated with differences in the rate of AD medication use during
meta-regression. Funnel plot of the rate of AD medication use on the log scale plotted
against study size reveals no asymmetry to suggest publication bias (Figure 4.33).
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Figure 4.32 Forrest plot of studies reporting on rates of AD medication use. Point
estimates are provided along with 95% confidence intervals for each study and the pooled
estimate. Studies are arranged in increasing order of size.
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Figure 4.33 Funnel plot showing rate of AD medication use (ln(odds)) against study size.
No evidence of asymmetry to suggest publication bias.
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Mean Number of Bowel Movements/ 24 hours
Twenty seven studies totaling 8,336 patients reported on the mean number of
bowel movements (BM) within 24 hours, with individual study estimates ranging
between 4.2-7.8 BM/24hrs25, 27-30, 32, 35, 40, 43, 44, 46, 47, 52-54, 58, 59, 63, 64, 68, 76, 78, 81, 83, 89, 91, 93.
The pooled estimate including all studies was 5.6 BM/24 hrs (95% CI, 5.3-5.9) with
significant heterogeneity p = <0.001 and I2 at 99.1% (Table 4.5). Figure 4.34 graphically
summarizes each study estimate, its 95% confidence interval, and the pooled estimate.
Studies with ≥85% J-pouch and with follow up of at least 5 years both had slightly higher
mean number of BM/ 24hrs, 6.1 (95% CI,5.6-6.5) and 5.8 (95% CI, 5.5-6.1) respectively.
Restricting the analysis to studies with ≥85% diverting ileostomy and < 10% follow-up
had little effect on the summary estimate (Table 4.6). At the study level, proportion of Jpouch (p = 0.01, Figure 4.35) was associated with a higher mean number of BM/24 hrs,
accounting for 17.02% of between study variability, while study type and mid-point year
lost their association with multivariable meta-regression. Funnel plot of the mean number
of BM/24 hrs against study size reveals evidence of publication bias with few small
studies being published with higher mean number of BM/24 hrs (Figure 4.36).
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Figure 4.34 Forrest plot of studies reporting mean number of BM/ 24 hrs. Point estimates
are provided along with 95% confidence intervals for each study and the pooled estimate.
Studies are arranged in increasing order of size.
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Figure 4.35 Meta-regression of studies with ≥85% J-pouch (0 =<85% J-pouch, 1 = ≥85%
J-pouch) on mean number of BM/ 24hrs. Studies with a higher rate of J-pouch had more
BM in 24hrs, accounting for 17.02% of between study variability (p = 0.01). The area of
the circle is proportional to the number of patients in each study.
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Figure 4.36 Funnel plot showing rate mean number of BM/ 24hrs against study size.
Lack of studies in bottom right hand corner indicates a lack of small studies being
published with higher number of BM/24 hrs.
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Mean Number of Bowel Movements/ Night
Fifteen studies totaling 5,594 patients reported on the mean number of bowel
movements (BM) at night, with individual study estimates ranging between 0.3-1.7
BM/night28-30, 35, 44, 46, 54, 58, 63, 64, 76, 78, 83, 89, 91. The pooled estimate including all studies
was 1.0 BM/night (95% CI, 0.8-1.2) with significant heterogeneity p = <0.001 and I2 at
99.0% (Table 4.5). Figure 4.37 graphically summarizes each study estimate, its 95%
confidence interval, and the pooled estimate. Subgroup analysis failed to reveal any
differences in mean number of BM/ night (Table 4.6). Similarly, univariable metaregression failed to identify any significant associations between study level factors and
mean number of BM/night. Funnel plot of mean number of BM/night did not reveal any
asymmetry to suggest publication bias.
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Figure 4.37 Forrest plot of studies reporting mean number of BM/ night. Point estimates
are provided along with 95% confidence intervals for each study and the pooled estimate.
Studies are arranged in increasing order of size.
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Figure 4.38 Funnel plot of mean number of BM/ night fails to reveal any significant
asymmetry to suggest publication bias.

126
Table 4.5 Meta-Analysis of Functional Results Following IPAA
Function
Number Number of Pooled % 95% CI
of Studies
Patients
Fecal
30
9,284
13.2
9.9-17.3
incontinence
Urgency
14
3,434
8.8
6.4-12.2
Pad use
20
7,341
13.7
10.6-18.1
Anti-diarrheal
24
6,153
32.9
27.3-39.4
meds
Mean number
27
8,336
5.6
5.3-5.9
of BM/24 hrs
Mean number
15
5,594
1.0
0.8-1.2
of BM/night

Heterogeneity
I2(%)
p
96.9
<0.001
88.2
94.8
95.1

<0.001
<0.001
<0.001

99.1

<0.001

99.0

<0.001

BM bowel movements

Table 4.6 Subgroup Meta-Analysis of Functional Results Following IPAA
Sub-Group

No.
Studies

No.
of Patients

Pooled %

95% CI

Heterogeneity
I2
p

≥85% J-pouch
Fecal incontinence
Fecal urgency
Daily pad use
Anti-diarrheal medication
Mean number of BM/24hrs
Mean number of BM/night

8
5
6
6
10
6

3,350
804
2,754
2,689
3,878
2,675

9.1
3.9
6.0
35.2
6.1
1.1

3.3-24.5
2.4-6.4
2.1-16.5
27.6-43.7
5.6-6.5
0.8-1.4

98.4
47.8
96.3
90.7
97.1
98.8

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

≥85% Diverting ileostomy
Fecal incontinence
Fecal urgency
Daily pad use
Anti-diarrheal medication
Mean number of BM/24hrs
Mean number of BM/night

13
4
11
12
17
10

5,074
589
4,702
4,091
6,288
4,856

14.9
5.7
15.8
29.6
5.4
1.1

9.4-22.9
2.8-11.5
11.3-21.8
21.3-39.6
5.2-5.7
0.8-1.4

97.7
76.5
94.8
96.8
99.1
98.8

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

Follow-up ≥ 5yrs
Fecal incontinence
Fecal urgency
Daily pad use
Anti-diarrheal medication
Mean number of BM/24hrs
Mean number of BM/night

9
5
10
8
11
6

5,362
2,066
5,387
3,270
5,156
3,905

15.9
9.8
13.7
29.9
5.8
1.1

9.6-25.4
5.8-16.1
9.4-19.5
22.8-38.0
5.5-6.1
0.9-1.4

98.4
91.7
90.1
93.8
98.9
97.7

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

< 10% lost to follow-up
Fecal incontinence
Fecal urgency
Daily pad use
Anti-diarrheal medication
Mean number of BM/24hrs
Mean number of BM/night

20
9
10
15
14
8

7,029
2,661
5,000
4,774
4,851
3,455

13.8
11.5
17.1
32.2
5.5
1.0

9.5-19.7
6.4-12.2
12.2-23.5
25.2-39.9
5.3-5.8
0.6-1.4

97.5
88.7
95.8
95.8
97.8
99.5

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
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4.3 Discussion
This systematic review summarizes the literature reporting on clinical outcomes
following IPAA, and includes 67 studies reporting on 21,882 patients. These studies
varied greatly in their patient characteristics, operative approaches, and methodologic
rigor. In an attempt to account for the significant between study heterogeneity, we carried
out multiple sensitivity analyses and meta-regressions along both clinical variables and
methodologic criteria.
One of the most severe complications following this procedure is pouch failure
resulting in pouch removal and/or permanent ileostomy. The pooled incidence was 5.5%,
which was significantly lower amongst those studies which predominantly reported on
patients with J-pouch configuration (pooled incidence 3.8%), and higher amongst those
studies with at least five years of follow-up (6.3%). No doubt as length of follow-up
increases, so does the rate of pouch failure as patients may develop pouchitis over time
necessitating diversion or pouch removal. The influence of pouch type on results was also
seen for functional outcomes. Studies reporting on patients with J-pouch configuration
(as opposed to a S- or W- pouch) had improved pouch function as evidenced by lower
rates of fecal incontinence, fecal urgency, and daily pad use when compared to other
studies using meta-regression. This finding is supported by a meta-analysis looking
specifically at pouch configuration that found the J-pouch had higher number of BM/ day
but lower rates of other complications95. Similarly, the mean number of bowel
movements per 24 hours among studies reporting on patients with J-pouch configuration
was significantly higher than those reporting on other pouch configurations with a mean
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of 6.1 BM/24 hrs among those with J-pouch. Given that most surgeons now use the Jpouch configuration and that a consistent association with this subgroup and most
functional outcomes reported in this anaysis was observed, we decided to use this
subgroup of studies to populate our decision aid with functional outcomes.
Of the methodologic criteria examined using meta-regression, outcome definition
was consistently associated with an increase in complication rates for most of the clinical
outcomes (pouch fistula, anastomotic stricture, pouchitis, and small bowel obstruction).
This implies that studies using well defined outcome criteria are capturing more patients
with those complications. This likely protects against reporting bias by standardizing the
assessment of the outcomes and resulting in more reliable complication rates. Other
methodologic criteria including prospective design, consecutive patient recruitment,
proportion loss to follow-up, and use of a standardized follow-up protocol were not
consistently found to influence the rate of complications reported in individual studies.
There is no empiric evidence available to guide the selection of quality criteria when
assessing observational studies6, 7, although with this analysis we have shown a consistent
association between the use of clearly defined outcome criteria and rate of most
complications reported in these studies. Thus, outcome criteria definition should be
strongly considered as a quality measure when assessing observational studies reporting
on complications following surgery.
Other study level factors we explored using meta-regression included proportion
of patients with Crohn’s disease, indeterminate colitis, and FAP. Proportions of these
alternate diagnoses among studies were not associated with rates of outcomes. Studies
designed to specifically look at the influence of these other diagnoses on the results of
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restorative pouch procedures have documented higher rates of complications in patients
with Crohn’s disease and indeterminate colitis75. In a meta-analysis looking specifically
at patients with Crohn’s disease who had undergone a restorative pouch procedure, the
failure rate was 32%96.Despite a strong association with outcomes in other studies,
prevalence of Crohn`s disease was not associated with outcomes during our metaregression. This lack of association seen at the study level likely reflects the low
prevalence of Crohn’s disease among the studies included with only 18 of 67 studies
including patients with Crohn’s disease and of those most accounted for <5% of patients.
Similarly, the proportion of patients with FAP and indeterminate colitis in the included
studies was low as well.
Study level factors dealing with operative technique examined with metaregression included proportion of patients who received a stapled anastomosis and
proportion of patients with defunctioning ileostomy. No association at the study level
between the proportion of patients with a defunctioning ileostomy and complication rates
was identified. A meta-analysis of observational studies comparing patients with and
without diversion did show that patients who forgo diversion are at increased risk of
pouch-related septic complications22. Most studies included in this review reported 80%
or greater rates of diversion, thus the un-diverted group likely account for too few
patients to affect the results. Similarly, no association was found between the proportion
of patients who underwent a stapled anastomosis and complication rates.
Comparing our results to those of the only other systematic review and metaanalysis of IPAA studies, our overall pooled rates of complications tended to be slightly
less than that reported by Hueting et al.3 For example, our pooled rate of pouch failure
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was 5.5% versus 6.8% in the former review. This could be the result of our study
focusing on larger patient series (100 or greater patients) or more modern series, as their
review was limited to studies published up to 2000. As surgeons gain experience, results
will improve and this may be a reflection of this. Other complex surgical procedures have
been found to have a volume-outcome relationship, with better outcomes arising amongst
those surgeons with higher volumes97, 98. Our review not only updates that of the previous
authors, but includes an in-depth analysis of between study heterogeneity utilizing
subgroup analysis, meta-regression, and funnel plots to examine for publication bias.
With the exception of use of anti-diarrheal medications and mean number of BM/
night, every outcome studied showed evidence of publication bias with smaller studies
predominantly reporting on lower complication rates. Presumably, this results from the
difficulty or unwillingness to publish smaller studies with poorer results, similar to
negative comparative trials99. By using a random effects model to combine complication
rates, studies were weighted based on a combination of within study and between study
variability. Given the high degree of between study variability, smaller studies are given
more relative weight then they would if the between study variability were less, with
weights more reflective of study size. This in combination with the lack of smaller studies
reporting higher complication rates probably lead to an under-estimation of true pooled
complication rates.
One way to deal with this problem is to restrict the meta-analysis to larger studies
whose outcome distributions are more symmetrical10. We conducted a sensitivity analysis
of all outcomes on study size by comparing studies with at least 250 patients to those
with 100-249 patients and found little difference in pooled outcomes. For example, the

131
pooled pouch failure rate amongst studies with ≥ 250 patients was 5.2% (95% CI, 4.46.1) and 5.6% (95% CI, 4.5-6.9) among those with 100-249 patients. This indicates that
although the funnel plots suggest publication bias, the degree of between study
heterogeneity likely outweighs any influence publication bias has on the summary
estimates. This can be visualized by the number of studies that fall outside the 95%
confidence limits of the funnel plots (Figure 4.3) which occurs over the entire plot, not
just at the base.
Other methods do exist to adjust for the presence of publication bias. Methods
based on regression equations and adjustment of summary estimates have been
developed, however they have been found to perform poorly when the I2 value reaches
50%, and thus were not used in this study100. Although the funnel plots suggest
publication bias for most outcomes, with fewer small studies reporting on higher
complication rates following IPAA, the degree of between study heterogeneity exerts a
much larger influence on pooled outcomes.
Along with pouch failure, one of the more significant complications following
IPAA is pouchitis. Characterized by poor pouch function, pain, urgency, and multiple
bloody bowel movements, this complication can be detrimental to a patient’s quality of
life101. The pooled rate of pouchitis was 22%, with individual study ranges from 2-60%.
When study level factors were explored, the rate of pouchitis was higher among studies
with at least five years of follow-up (28%) and among studies that utilized clearly defined
outcome criteria (28%). We were not able to evaluate what specific criteria were used to
define pouchitis in each individual study as they varied greatly, from no criteria to
rigorous programs involving endoscopic surveillance and biopsies of the pouch. This
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highlights one of the limitations of this meta-analysis and likely accounts for some of the
residual between study heterogeneity that we were unable to account for despite
sensitivity analyses and meta-regressions. Studies using different outcome criteria will
result in varying rates of pouchitis, as with other outcomes. The challenge we faced was
our desire to summarize the literature into point estimates that we could include into a
decision aid for patients, while running the risk of combining studies that were measuring
different things. As evidenced by the large I2 values, even after sensitivity analyses and
meta-regression, there clearly remains significant between-study heterogeneity, likely the
result of un-accounted for study level differences in specific outcome criteria, population
parameters, and study design.
Despite its utility in exploring heterogeneity and guiding our selection of which
group of studies to include in our decision aid, meta-regression is not without its own
limitations and cautions. A major limitation is that meta-regression of observational trials
are still limited by the quality and potential bias inherent in the individual trials24.
Another caution is the use of meta-regression to identify associations between study level
factors and use this to imply an association at the patient level, a situation known as
aggregation bias or ecological fallacy102. For example, if we had identified an association
between a higher proportion of diverted patients and pelvic sepsis, then we may have
concluded that diversion results in a higher risk of pelvic sepsis, when in actual fact, at
the patient level, all the patients in the studies that had this complication were in the undiverted group and differences in other risk factors accounted for the study level
association. This type of bias is difficult to detect without patient level data, and thus any
patient level causal inferences made on the basis of study level associations must be
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viewed with caution103. Another limitation of meta-regression is that it often suffers from
low power, due to smaller numbers of included studies103. To combat this, most authors
recommend that no more than 1 study level covariate be explored for every 10 studies in
the meta-analysis24, 103. This ratio was used to guide the number of covariates we included
in our multivariable meta-regression. Another limitation is the potential for data dredging
and multiplicative testing with possible false positive associations. Most authors
recommend pre-specifying the covariates to be examined, as we did in this study.
Another strategy is to apply a Bonferroni adjustment to the significance level24 of each
covariate. We elected not to do this as we had pre-specified our covariates of interest, and
our analyses were exploratory in nature, trying to explain heterogeneity, not to make
causal inferences. At the statistical level, certain considerations are important to properly
conduct a meta-regression. We used a random-effects meta-regression which accounts for
both between study and within study variance, this the recommend approach as no set of
covariates will completely explain all the heterogeneity present, thus this must be
accounted for in the analysis24.
No established protocol exists for the selection of which studies to include when
conducting a meta-analysis with a view towards populating a decision aid with outcome
estimates. We applied a systematic assessment of between study heterogeneity using
subgroup analyses and meta-regression in an effort to guide the selection of appropriate
studies to include in the summary estimate destine to be included in the decision aid. For
those outcomes that were significantly influenced by length of follow-up (pouch failure,
pouchitis) these point estimates were used, while for studies that showed an association
with outcome definition (pouch fistula, anastomotic stricture, small bowel obstruction)
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these subgroups were used. Pelvic sepsis showed an association with prospective design,
and this was selected as the group for that outcome. While functional results were taken
from the subgroup of studies reporting on 85% or greater J-pouch patients as there was a
consistent association with functional outcomes and this subgroup in the meta-regression.
Despite significant residual between-study heterogeneity, we executed a large,
inclusive review with systematic and rigorous exploration of heterogeneity that revealed a
consistent association with outcome criteria definition and complication rates, thus
adding some empiric evidence to its use as a quality criterion for the reporting of
observational surgical trials. We also used the results of the meta-regression to guide the
inclusion of studies into the decision aid’s point estimates. The next chapter will
summarize the systematic review of studies reporting on the outcomes following
ileostomy, while chapter six will outline the methodology necessary in the refinement and
initial testing of the prototype decision aid.
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CHAPTER FIVE-SYSTEMATIC REVIEW AND META-ANALYSIS OF OUTCOMES
FOLLOWING PROCTOCOLECTOMY AND ILEOSTOMY
5.0 Introduction
The traditional option for patients with ulcerative colitis requiring surgery is total
proctocolectomy and end-ileostomy. This technique involves suturing the end of the
small bowel (the ileum) to the skin and everting it along the fashion described by Brooke,
in an effort to minimize skin based complications1. This is touted as the gold standard for
the management of ulcerative colitis and has been performed since the 1950’s. Despite its
long history and successful track record, this procedure is not without its own share of
long-term problems, largely the result of complications related to the ileostomy. In order
to provide patients with information necessary to decide between having an ileostomy or
a restorative pouch procedure, it is necessary to summarize the risks of a long-term
ileostomy. In order to populate our decision aid, we undertook a systematic review and
meta-analysis of outcomes following protcolectomy and ileostomy with a focus on
ileostomy-based complications. This information is important to patients who are
deciding between living with a long-term ileostomy or contemplating conversion to a
restorative pouch procedure. An ileostomy, although technically simple to construct, is
fraught with numerous long-term problems which must be balanced by the risks of IPAA
when patients are deciding between the two options.
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5.1 Methods
Search Strategy
The overall search strategy is outlined in chapter two of this work. We included
studies reporting on outcomes following colectomy and ileostomy for patients with
ulcerative colitis who reported on at least 100 patients. All titles and abstracts were
independently reviewed by two reviewers and any study that either reviewer deemed as
potentially eligible was selected for full text review. Study inclusion was then assessed
independently with any disagreement resolved by consensus.
Data Extraction
Full text papers were reviewed, and for all studies that met our inclusion criteria,
data was extracted independently by two reviewers with any disagreement resolved by
consensus using standardized data-abstraction sheets. Study characteristics including size,
location, time period of patient enrollment, length of follow-up, mean age of patients,
proportion with Crohn’s disease, FAP, or indeterminate colitis, proportion with prior
subtotal colectomy, and proportion with excision of rectum were abstracted. Outcomes of
interest included ileostomy revision (any procedure undertaken to revise the ileostomy
regardless of method or indication), ileostomy stenosis, ileostomy prolapsed, ileostomy
fistula, ileostomy retraction, small bowel obstruction requiring surgery, and parastomal
hernia requiring surgery.
Quality Criteria
A detailed discussion of the rationale behind the selection of quality criteria is
found in chapter two of this work. We selected specific elements of study design
reflective of quality and reported on them rather than used established tools as there is no
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empirical evidence linking any one tool or set of criteria to study validity for
observational studies2, 3. The elements of quality examined included: whether or not the
patients represented a group of consecutive patients having surgery over a pre-specified
time period, whether the authors used clearly defined outcome criteria, whether the study
was retrospective or prospective, proportion loss to follow-up, and whether they
employed a standardized follow-up procedure.
Meta-Analysis
Each study estimate of a given outcome was recorded and its 95% confidence
interval was determined using Wilson’s score method4. In order to combine the
proportions from individual studies, we converted the individual proportions into odds5,
and the odds was transformed into the log scale using equation 4.1:
ln(odds) = ln (no of patients having event/ no of patients not having event) (4.1)
This allowed us to generate a variance term which was used in the weighting of studies
for the meta-analysis(equation 4.2):

var ln(odds) = 1/No of patients having event + 1/ no of patients not having event5 (4.2).

Meta-analysis was then carried out of individual study proportions converted to
the ln(odds) scale according to the random-effects model of DerSimonian and Laird6,
accounting for both within-study variance and between-study variance. This model
assumes that the outcome measures of each study come from a random distribution of
outcomes, with the weighting of studies based on the reciprocal of the sum of between
study variance and within study variance. The statistical package, STATA version 10
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(Stata inc, Texas, US, 2008) using the procedures meta and metan were used to metaanalysis the data as described by Sharp7. This procedure estimates the between-study
variance using the non-iterative weighted method of DerSimonian and Laird6. Pooled
results were converted back to the proportion scale and presented along with their 95%
confidence interval. In case were the study had no events, a continuity correction factor
was added (0.5) in order to generate an outcome measure for the meta-analysis as ln(0) is
not a real number. Adding a continuity correction is preferred over excluding studies with
zero events8. Each outcome was also graphically summarized using Forrest plots. The
possibility of publication bias was explored using funnel plots of the individual
outcomes, looking for asymmetry amongst the smaller trials. This was done assuming
smaller trials might be more apt to get published if they have “better” results, ie lower
rates of complications following surgery.

Heterogeneity
Heterogeneity was assessed for each outcome using the Cochran’s Q chi-squared
test which is calculated by adding together the squared deviations of each study’s
outcome from the overall pooled outcome, adjusting each deviation by the study’s weight
used in the meta-analysis9. The degree of heterogeneity was also quantified using the I2
statistic, which is the percentage of total variation across studies that is due to
heterogeneity rather than chance10. The resulting value ranges from 0 (no heterogeneity)
to 100, with an increasing amount of heterogeneity as the % I2 increases. There were too
few studies to conduct any meaningful subgroup analyses or meta-regression.
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5.2 Results
5.2.1 Study Selection
We reviewed 3,920 abstracts and titles, of which 411 were selected for full-text
review. Of these, 11 reported on the outcomes of colectomy and end-ileostomy for
patients with ulcerative colitis. Agreement between reviewers for this subset of studies
was excellent (k = 0.78).
5.2.2 Study Description and Quality
The 11 studies included 3,859 patients from five different countries, reporting on
patients operated on from 1950 to 2005. Most of the studies were retrospective in nature
and were of non-consecutive patients (Table 5.1). Two of the studies reported on the
results of patient questionnaires, one from the US and the other from Australia. Only one
study was prospective and it was also the only study with a standardized follow-up
protocol. Only 3 of the 11 studies defined some of their outcome criteria, and length of
follow-up was only recorded in three studies, with mean follow-up of 96, 110, and 139
months (Table 5.2). Only four of the studies reported exclusively on patients with
ulcerative colitis. Patients with Crohn’s disease were included in 6 studies with
proportions ranging from 9.1% to 39.3%, while 3 studies included patients with FAP,
ranging from 1.3% to 4%. Of the 11 studies, 6 studies exclusively reported on the results
of total proctocolectomy, while two studies reported on the results of subtotal colectomy
and ileostomy. The rate of proctocolectomy varied from 54.7% to 90.9% among the
remaining three studies. Only two of the studies reported on loss to follow-up, the two
patient questionnaire studies, which had response rates of 51.5% and 53.6%.
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Table 5.1 Characteristics of Studies Reporting on Outcomes Following Colectomy and Ileostomy
Author

Location

Years of
Surgery
1960-1970

Consecutive
Patients
No

Oslo, Norway

1969-1978

No

Morowitz and
Kirsner11, 1981
Albrechtsen et al12,
1981
Bokey et al, 198413

US (multiple states)

Sydney, Australia

1950-1981

No

Bauer et al14, 1986
Berry et al15, 1986
Carlstedt et al16,
1987
Leong et al17, 1994
Leijonmarck et al,
199218
Carlsen and
Bergan19, 1995
Karch et al20, 1995
Brady et a21, 2008

New York, US
Oxford, UK
Goteberg, Sweden

1973-1984
1972-1984
1959-1984

London, UK
Stockholm, Sweden

Type of Study
Patient
Questionnaire
Retrospective

Outcome
Defined
None

Standardized
Follow-up
No

Some

No

None

No

No
No
Yes

Patient
Questionnaire
Retrospective
Retrospective
Prospective

Some
None
None

No
No
Yes

1971-1980
1955-1984

No
No

Retrospective
Retrospective

None
None

No
No

Oslo, Norway

1980-1989

No

Retrospective

None

No

New York, US
Edinburgh, UK

1988-1993
1994-2005

Yes
Yes

Retrospective
Prospective

None
Some

No
No
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Table 5.2 Characteristics of Patients in Studies Reporting on Ileostomy and Colectomy.
Author

Morowitz and
Kirsner11, 1981
Albrechtsen et al12,
1981
Bokey et al, 198413
Bauer et al14, 1986
Berry et al15, 1986
Carlstedt et al16, 1987
Leong et al17, 1994
Leijonmarck et al,
199218
Carlsen and Bergan19,
1995
Karch et al20, 1995
Brady et a21, 2008
NR not recorded

N

%
Crohn’s

%
FAP

%
IC

% Removal
of Rectum

% Priorsubtotal

1803

Patient Mean
Age (Range)
y
35 (3-79)

NR

Length of
Follow-up
(months)
NR

Loss to
Follow-up
(%)
51.5

0

0

0

70.5

154

34.7 (12-76)

0

0

0

90.9

0

NR

0

354
427
115
104
150
255

49
NR
33
34
42 (14-76)
NR

10
9.1
23.5
0
39.3
0

4
0
0
0
1.3
0

0
0
0
0
0
0

100
100
100
100
54.7
100

NR
NR
18.3
NR
NR
NR

NR
NR
NR
96
110
139.2

53.6
NR
0
0
NR
0

224

NR

24.1

3.5

0

100

NR

NR

NR

114
159

37 (13-79)
41.9 (13-89)

14.9
0

0
0

3.5
0

0
0

NR
NR

NR
NR

NR
NR
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5.2.3 Complications
Ileostomy Revision
Ten studies totaling 3,432 patients reported on the rate of ileostomy revision with
individual study estimates ranging from 0.6% to 31.2%11-13, 16-19. The pooled estimate was
17.1% (95% CI, 13.1%-22.1%) with significant heterogeneity p = <0.001, I2 at 86.4%
(Table 5.3). Figure 5.1 graphically summarizes each study estimate, 95% confidence
interval, and pooled estimate. Looking at the largest study, the questionnaire of 1,803
patients, the rate of revision within that study was 22.4%. Limiting the studies to ones
that only reported on patients with ulcerative colitis resulted in a pooled rate of ileostomy
revision of 14.5% (95%CI, 9.1%-22.2%) for 5 studies reporting on a total of 2,475
patients. A funnel plot (Figure 5.2) shows evidence of publication bias with fewer smaller
studies being published with higher rates of ileostomy revision. Depending on the study
the most common causes for revision were either stenosis or retraction of the ileostomy.
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Figure 5.1 Forrest plot of studies reporting on rates of ileostomy revision. Point estimates
are provided along with 95% confidence intervals for each study and the pooled estimate.
Studies are arranged in increasing order of size.
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-2
0
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2

Figure 5.2 Funnel plot showing rate of ileostomy revision (ln(odds)) against study size.
Lack of studies in bottom right hand corner indicates a lack of small studies being
published with higher rates of ileostomy revision.
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Ileostomy Stenosis
Seven studies totaling 3,044 patients reported on the rate of ileostomy stenosis
requiring therapy with individual study estimates ranging from 0.6% to 13.5% 11-13, 15-21.
The pooled estimate was 5.7% (95% CI, 3.5%-9.5%) with significant heterogeneity p =
<0.001, I2 at 85.5% (Table 5.3). Figure 5.3 graphically summarizes each study estimate,
95% confidence interval, and pooled estimate. Looking at the largest study, the
questionnaire of 1,803 patients, the rate of stenosis within that study was 5.6%. Limiting
inclusion to studies that only reported on patients with ulcerative colitis resulted in a
pooled rate of stenosis of 7.3% (95%CI, 3.9%-13.3%) for 4 studies reporting on a total of
2,316 patients. A funnel plot (Figure 5.4) shows evidence of publication bias with fewer
smaller studies being published with higher rates of ileostomy stenosis.
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Figure 5.3 Forrest plot of studies reporting on rates of ileostomy stenosis. Point estimates
are provided along with 95% confidence intervals for each study and the pooled estimate.
Studies are arranged in increasing order of size.
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Figure 5.4 Funnel plot showing rate of ileostomy stenosis (ln(odds)) against study size.
Lack of studies in bottom right hand corner indicates a lack of small studies being
published with higher rates of ileostomy stenosis
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Ileostomy Retraction
Six studies totalling 2,894 patients reported on the rate of ileostomy retraction,
with individual study estimates ranging from 5.3% to 18.0% 11-13, 16, 18, 19. The pooled
estimate was 6.2% (95% CI, 2.7%-13.3%) with significant heterogeneity p = <0.001, I2 at
95.0% (Table 5.3). Figure 5.5 graphically summarizes each study estimate, 95%
confidence interval, and pooled estimate. Looking at the largest study, the questionnaire
of 1,803 patients, the rate of ileostomy retraction within that study was 12.8%. Limiting
inclusion to studies that only reported on patients with ulcerative colitis resulted in a
pooled rate of retraction of 11.3% (95%CI, 6.1%-20.1%) for 4 studies reporting on a total
of 2,316 patients. A funnel plot (Figure 5.6) shows evidence of publication bias with
fewer smaller studies being published with higher rates of ileostomy retraction.

156

Figure 5.5 Forrest plot of studies reporting on rates of ileostomy retraction. Point
estimates are provided along with 95% confidence intervals for each study and the pooled
estimate. Studies are arranged in increasing order of size.
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Figure 5.6 Funnel plot showing rate of ileostomy retraction (ln(odds)) against study size.
Lack of studies in bottom right hand corner indicates a lack of small studies being
published with higher rates of ileostomy retraction
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Ileostomy Prolapse
Seven studies totalling 3,044 patients reported on the rate of ileostomy prolapse,
with individual study estimates ranging from 0.6% to 10.5% 11-13, 16-19. The pooled
estimate was 3.1% (95% CI, 1.5%-6.4%) with significant heterogeneity p = <0.001, I2 at
88.4% (Table 5.3). Figure 5.7 graphically summarizes each study estimate, 95%
confidence interval, and pooled estimate. Looking at the largest study, the questionnaire
of 1,803 patients, the rate of ileostomy prolapse within that study was 10.5%. Limiting
the studies to ones that only reported on patients with ulcerative colitis resulted in a
pooled rate of prolapse of 3.6% (95%CI, 1.4%-9.8%) for 4 studies reporting on a total of
2,316 patients. A funnel plot (Figure 5.8) shows evidence of publication bias with fewer
smaller studies being published with higher rates of ileostomy prolapse.
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Figure 5.7 Forrest plot of studies reporting on rates of ileostomy prolapse. Point
estimates are provided along with 95% confidence intervals for each study and the pooled
estimate. Studies are arranged in increasing order of size.
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Figure 5.8 Funnel plot showing rate of ileostomy prolapse (ln(odds)) against study size.
Lack of studies in bottom right hand corner indicates a lack of small studies being
published with higher rates of ileostomy prolapse.
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Ileostomy Fistula
Six studies totalling 2,940 patients reported on the rate of ileostomy fistula, with
individual study estimates ranging from 0.6% to 9.4% 11-13, 17-19. The pooled estimate was
4.8% (95% CI, 2.7%-8.3%) with significant heterogeneity p = <0.001, I2 at 85% (Table
5.3). Figure 5.9 graphically summarizes each study estimate, 95% confidence interval,
and pooled estimate. Looking at the largest study, the questionnaire of 1,803 patients, the
rate of ileostomy fistula within that study was 9.0%. Limiting the studies to ones that
only reported on patients with ulcerative colitis resulted in a pooled rate of ileostomy
fistula of 3.1% (95%CI, 0.8%-8.3%) for 3 studies reporting on a total of 2,212 patients. A
funnel plot (Figure 5.10) shows evidence of publication bias with fewer smaller studies
being published with higher rates of ileostomy fistula.
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Figure 5.9 Forrest plot of studies reporting on rates of ileostomy fistula. Point estimates
are provided along with 95% confidence intervals for each study and the pooled estimate.
Studies are arranged in increasing order of size.
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Figure 5.10 Funnel plot showing rate of ileostomy fistula (ln(odds)) against study size.
Lack of studies in bottom right hand corner indicates a lack of small studies being
published with higher rates of ileostomy fistula.
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Parastomal Hernia
Seven studies totalling 3,005 patients reported on the rate of parastomal hernia
requiring repair, with individual study estimates ranging from 0.9% to 10.0% 11-13, 15, 17-19.
The pooled estimate was 3.5% (95% CI, 2.0%-6.1%) with significant heterogeneity p =
<0.001, I2 at 80.8% (Table 5.3). Figure 5.11 graphically summarizes each study estimate,
95% confidence interval, and pooled estimate. Looking at the largest study, the
questionnaire of 1,803 patients, the rate of parastomal hernia within that study was 6.3%.
Limiting the studies to ones that only reported on patients with ulcerative colitis resulted
in a pooled rate of parastomal hernia of 4.1% (95%CI, 2.1%-7.9%) for 3 studies reporting
on a total of 2,162 patients. A funnel plot (Figure 5.12) shows evidence of publication
bias with fewer smaller studies being published with higher rates of parastomal hernia.
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Figure 5.11 Forrest plot of studies reporting on rates of parastomal hernia. Point
estimates are provided along with 95% confidence intervals for each study and the pooled
estimate. Studies are arranged in increasing order of size.
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Figure 5.12 Funnel plot showing rate of parastomal hernia (ln(odds)) against study
standard size. Lack of studies in bottom right hand corner indicates a lack of small studies
being published with higher rates of parastomal hernia
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Small Bowel Obstruction
Seven studies totalling 2,849 patients reported on the rate of small bowel
obstruction requiring operation, with individual study estimates ranging from 1.8% to
18.0% 11-13, 15, 17, 19, 20. The pooled estimate was 9.1% (95% CI, 6.5%-12.8%) with
significant heterogeneity p = <0.001, I2 at 78.5% (Table 5.3). Figure 5.13 graphically
summarizes each study estimate, 95% confidence interval, and pooled estimate. Looking
at the largest study, the questionnaire of 1,803 patients, the rate of small bowel
obstruction requiring operation within that study was 12.7%. Limiting the studies to ones
that only reported on patients with ulcerative colitis resulted in a pooled rate of small
bowel obstruction of 7.7% (95%CI, 3.8%-15.3%) for 3 studies reporting on a total of
2,116 patients. A funnel plot (Figure 5.14) shows evidence of publication bias with fewer
smaller studies being published with higher rates of small bowel obstruction.
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Figure 5.13 Forrest plot of studies reporting on rates of small bowel obstruction. Point
estimates are provided along with 95% confidence intervals for each study and the pooled
estimate. Studies are arranged in increasing order of size.
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Figure 5.14 Funnel plot showing rate of small bowel obstruction (ln(odds)) against study
size. Lack of studies in bottom right hand corner indicates a lack of small studies being
published with higher rates of small bowel obstruction
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Table 5.3 Results of Meta-Analysis of Complications Following Colectomy and
Ileostomy
Complication
(ileostomy)
Revision
Total
UC only
Stenosis
Total
UC only
Retraction
Total
UC only
Prolapse
Total
UC only
Fistula
Total
UC only
Parastomal
hernia
Total
UC only
Small Bowel
Obstruction
Total
UC only

Number
of
Studies

Number of
Patients

Pooled %

95% CI

Heterogeneity
I2(%)
p

10
5

3,432
2,475

17.1
14.5

13.1-22.1
9.1-22.2

86.4
86.2

<0.001
<0.001

7
4

3,044
2,316

5.7
7.3

3.5-9.5
3.9-13.3

85.5
86.6

<0.001
<0.001

6
4
7
7
4

2,894
2,316
3,044
3,044
2,316

6.2
11.3
3.1
3.1
3.6

2.7-13.3
6.1-20.1
1.5-6.4
1.5-6.4
1.4-9.8

95.0
91.4
88.4
88.4
86.9

<0.001
<0.001
<0.001
<0.001
<0.001

6
3

2,940
2,212

4.8
3.1

2.7-8.3
0.8-8.3

85.0
84.2

<0.001
<0.001

7
3

3,005
2,162

3.5
4.1

2.0-6.1
2.1-7.9

80.8
69.1

<0.001
0.04

7
3

2,849
2,116

9.1
7.7

6.5-12.8
3.8-15.3

78.5
78.3

<0.001
0.003
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5.3 Discussion
Although technically simple when compared to reconstructive procedures,
proctocolectomy and ileostomy can also lead to significant long-term complications
related to the presence of the ileostomy. Ileostomy revision can be one of the most severe
problems as patients must have the ileostomy re-fashioned either at the same site or at an
entirely new site. The pooled rate of ileostomy revision for all studies was 17.1%, and
among studies limited to patients with ulcerative colitis, the rate was slightly lower at
14.5%. Of those studies that listed them, the most common indications for revision were
stenosis16, 19, retraction11, 18, or obstruction at the ileostomy site13. Ileostomy revision can
occur locally or can necessitate a full laparotomy with re-siting of the stoma to another
area of the abdominal wall. The rate of local-only repair varied between those studies that
reported it from 28% to83%16, 19. Patients with Crohn’s disease have a higher rate of
ileostomy revision when compared to ulcerative colitis. Carlsen et al reported the need
for ileostomy revision among Crohn’s patients was 59.3% versus 18.6% among those
with ulcerative colitis19. Similarly, in the only prospective study, Carlstedt et al identified
the need for revision among patients with Crohn’s disease was 44% versus 24% among
ulcerative colitis patients16.
The rate of peristomal fistula has also been found to be higher among patients
with Crohn’s disease16, 19. This was reflected by the lower rate of peristomal fistula when
our meta-analysis was restricted to those studies reporting solely on patients with
ulcerative colitis, 3.1% versus 4.8%. Interestingly, the rates of other stoma-related
complications were higher in the ulcerative colitis subgroup when compared to Crohn’s
disease (Table 5.3). Given that many comparative studies have shown that Crohn’s
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patients are at higher risk of stoma-related complications, this likely results from
differences in study design or characteristics relating to length of follow-up, outcome
definition, losses to follow-up, and other study-level factors. Given these differences in
outcome rates identified in the meta-analysis, we will limit the use of pooled outcomes
from studies solely reporting on patients with ulcerative colitis for inclusion in the
decision aid.
Like patients with restorative procedures, patients who have undergone a
proctocolectomy and ileostomy are at significant risk of small bowel obstructions
requiring operative therapy. The pooled estimate among studies solely reporting on
ulcerative colitis patients was 7.7%. Looking at the study with the longest reported
follow-up, the rate of small bowel obstruction was 18%17. This underscores the ongoing
risk for small bowel obstruction that carries on beyond the immediate post-operative
period. Length of follow-up likely plays a role in explaining the different rates of stomarelated complications, although it was not possible to examine this as only three studies
reported on the length of follow-up.
Only one study reported on the most common problem faced by ileostomates, that
of skin irritation. In Morowitz’s patients questionnaire, 1005 of 1803 (55.7%) patients
complained of significant skin irritation11. Although this rarely leads to ileostomy
revision, this complication can be distressing to patients and must also be considered by
those contemplating life with an ileostomy.
Although proctocolectomy and ileostomy is considered the benchmark to which
all other procedures for the treatment of ulcerative colitis are to be compared with22, 23,
there is a lack of methodologically sound studies reporting on the complications of this
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procedure. The quality of the studies reporting on outcomes following proctocolectomy
and ileostomy are even poorer than those presented in the preceding chapter of studies
reporting on IPAA. Only three of the studies reported on length of follow-up, only one of
seven studies was prospective, and very few defined any of their outcomes. In addition,
many of the studies reported on patients that were operated on in the 1950s and 1960s,
with less advanced peri-operative care than the modern era. This is important to consider
as the outcomes reported here will be included in a decision aid and compared to ones
from restorative procedures which were carried out during the 1980s -2000s. Given the
large number of patients who choose to undergo restorative procedures, it may be
difficult to obtain large numbers of patients who have had the conventional treatment of
proctocolectomy and ileostomy. In a study of over 25,000 ulcerative colitis patients of
whom 215 had a colectomy, only 29 patients had a total proctocolectomy and endileostomy24. This discrepancy in number of patients makes it difficult to compare the
results of ileostomy to those of IPAA. As was seen in the preceding chapter, there exists a
wealth of studies reporting on the results of IPAA, while only 11 studies were identified
that reported on the results of colectomy and ileostomy. This discrepancy is further
compounded by the very poor quality of the ileostomy studies. Each outcome reported in
the meta-analysis contained significant heterogeneity (Table 5.3). Unlike the IPAA
literature, there were too few studies to carry out any meta-regression or any meaningful
subgroup analyses to explore this heterogeneity.
Although severely limited by the small number of studies, historical nature
of patient cohorts, and poor study quality, we show that patients with ulcerative colitis
who undergo a total proctocolectomy and end-ileostomy do have a significant risk of
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ileostomy revision with a pooled estimate of 14.5% (95% CI, 9.1%-22.2%). Most other
stoma-related complications occur relatively infrequently (<10%); and patients are at risk
of requiring surgery for a bowel obstruction in the future, as high as 18% among studies
with longer follow-up. The risks of these potential complications along with the obvious
changes in body image, daily routine, and lifestyle must be considered by patients who
are deciding between IPAA and ileostomy.
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CHAPTER SIX- REFINEMENT AND TESTING OF PROTOTYPE DECISION AID
6.0 Introduction
A patient’s decision between treatment options is complex and requires the
assimilation of a large volume of information regarding complications and expected
outcomes. It is imperative that patients select the surgical procedure that best fits with
their own expectations and values. There is a paucity of data concerning effective
communication methods for patients with IBD1. Despite a paucity of data, patients with
ulcerative colitis who require surgery are faced with deciding between a restorative pouch
procedure or an ileostomy. Decision aids are tools designed to facilitate communication
of information to patients and enhance their ability to exercise treatment preferences2, 3.
At least 55 randomized controlled trials have evaluated different decision aids for
various medical decisions4. These trials have generally found the use of decision aids to
lead to improved patient knowledge, reduced decision conflict, and improved patient
satisfaction with treatment decisions, when compared with traditional methods of patientphysician interaction4. To our knowledge, no decision aids exist to assist patients with
ulcerative colitis in making this difficult surgical decision. Our objective is to develop
and evaluate a decision aid for patients with ulcerative colitis who are undergoing an
elective proctocolectomy to help them decide between IPAA and ileostomy. The general
aspects concerning both decision aids and ulcerative colitis and the role of surgery were
discussed in chapter one of this work. Surgery is generally reserved for patients who fail
medical management or who develop complications of ulcerative colitis (toxic colitis,
perforation, cancer or dysplasia). Two main options exist for the patient following
removal of the colon, either an ileostomy, where bowel movements are expressed into a
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bag worn on the skin of the abdomen, or formation of a neo-rectum by using the small
bowel as a pouch, known as ileal pouch-anal anastomosis (IPAA). Both options have
been shown to have equivalent quality of life as demonstrated by the systematic review of
these studies in Chapter Three. Despite equivalent quality of life, both options vary
greatly in their procedure, changes to daily life, and complication profiles. Two separate
systematic reviews and meta-analyses where conducted of studies reporting on
complications following either procedure (Chapter 4-IPAA studies, Chapter 5- ileostomy
studies), the results of which were used to construct a prototype decision aid. This pilot
aid will then be refined by input from surgeons, enterostomal therapists, and patients.
Following the refinement process, the aid will be tested for reliability and validity on
healthy volunteers before being used with patients. This chapter describes the
methodology behind this process and guides future endeavours aimed at further
refinement of the aid.

6.1. Methods
To develop the decision aid we used accepted methodology5-7 and followed
quality criteria established by an international committee on patient decision aids8. The
major steps involved in the development of this aid consist of gathering information,
initial decision aid prototype construction and refinement, and evaluation of the decision
aid on healthy volunteers for reliability and validity. Figure 6.1 outlines the major steps in
the development.
6.1.1 Information sources
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In order to determine what information to include in the decision aid we
conducted a systematic review of the literature for studies of proctocolectomy and either
ileostomy or IPAA. We have constructed a rough prototype based on the information
retrieved from the systematic review and plan on presenting this to colorectal surgeons
and enterostomal therapists to collect their input, and refine the prototype based on their
recommendations. Finally, we will present the aid to patients with ulcerative colitis who
have undergone either surgical option to identify information they feel is important in
reaching a decision and to further refine our prototype.

6.1.2 Systematic Review and Prototype Design
Chapters Four and Five detail the methods and results of the systematic reviews of
studies reporting on outcomes following either the IPAA option or the ileostomy option.
Given the between study heterogeneity, we selected specific sub-groups of studies to
include as a source of information for the aid. For the studies summarizing the results
following ileostomy, we limited the inclusion of the pooled estimates from those studies
that only reported on patients with ulcerative colitis, as we are dealing with this group of
patients. For the IPAA studies, we systematically explored both clinical and
methodologic study level factors for their influence on each outcome by using metaregression methods. Those with a significant association and a clinical rationale (for
example longer follow-up associated with higher rates of pouch failure) were used as the
subgroup of studies for inclusion into the decision aid. The following table lists the point
estimates used in the construction of the aid and the specific subgroup used as the source.
For each point estimate generated from the literature, we expressed it as x/100 for all
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outcomes. Utilizing a ratio with a common denominator is recommended by the
International Patient Decision Aid Standards Collaboration as a way to present
probabilities8. Along with a text-based description of the probabilities, we utilized a
pictorial representation of the risk of complications. The addition of visual
representations of risk have been shown to improve how easily and accurately patients
process quantitative information9. In addition, the format of the visual information
appears to affect the process with horizontally oriented pictographs being superior to
vertical formats and pie charts9, 10.

Table 6.1 Data Sources Used for Construction of the Decision Aid.
Intervention

Outcome

Point estimate

Subgroup

Ileostomy

Ileostomy revision

14.5% ~ 15/100

Ulcerative colitis

Ileostomy

Ileostomy stenosis

7.3%~ 7/100

Ulcerative colitis

Ileostomy

Ileostomy retraction

11.3 ~ 11/100

Ulcerative colitis

Ileostomy

Ileostomy fistula

3.1 ~ 3/100

Ulcerative colitis

Ileostomy

Parastomal hernia
requiring repair

4.1 ~ 4/10044

Ulcerative colitis

Ileostomy

Small bowel
obstruction

7.7 ~ 8/100

Ulcerative colitis

IPAA

Pouch failure

6.1 ~ 6/100

Follow-up >5years

IPAA

Pelvic sepsis

11.4~ 11/100

Prospective studies

IPAA

Pouch fistula

9.4%~ 9/100

IPAA

Anastomotic stricture

12.6~ 13/100

IPAA

Pouchitis

28.7% ~ 29/100

IPAA

Small bowel
obstruction

22.5% ~23/100

Defined outcome
criteria
Defined outcome
criteria
Defined outcome
criteria/ follow-up >5
yrs
Defined outcome
criteria
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IPAA

Sexual dysfunction

4.6% ~5/100

Overall group

IPAA

Fecal incontinence

9.1% ~ 9/100

≥ 85% J-pouch

IPAA

Fecal urgency

3.9% ~4/100

≥ 85% J-pouch

IPAA

Daily pad use

5.7% ~ 6/100

≥ 85% J-pouch

IPAA

Anti-diarrheal
medication use

32.9% ~ 33/100

Overall group

IPAA

Number of BM/day

6.1 ~ 6 / day

≥ 85% J-pouch

IPAA

Number of BM/ night

1.0 ~ 1/night

Overall group

We constructed the prototype aid along three categories: information about the procedure,
potential complications, and changes to daily life. This was constructed as an interactive power
point presentation that is designed to be used by the surgeon with the patient during the clinical
encounter. This can easily be modified and adapted into a pamphlet or be uploaded to the internet
for patient self-study. We selected this format as the aid is not meant to replace the surgeonpatient interaction, but rather enhance the process of information exchange11, and the
International Patient Decision Aid Standards Collaboration do support the use of the aid in a
guiding or coaching role during the patient-physician encounter8. In addition to presenting
information about the procedures, specific values-clarification exercises have been built into the
aid. The concept of values refers to the qualities that a given patient considers desirable or
important, and the process of value clarification has become part of decision aids4. In the most
recent systematic review, decision aids incorporating value clarification exercises were found to
be more effective than simpler aids by improving patients’ decisions and making them more
congruent with their values12.
Not all authors agree that value clarification has a role in decision aids. Nelson et al
question whether patients need explicit value clarification, and point out that intuitive decision
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making on the part of the patient may lead to better decisions as too much introspection and
attention to detail may disrupt intuitive processes and interfere with a patient’s ability to focus on
the relevant material, or inhibit the formation of global impressions leading to a decision being
made13. Despite these theoretical concerns, we opted to include a short segment on value
clarification, as the recent literature has shown it to be effective in improving the decision making
process. To help clarify a patient’s values, we listed a group of questions regarding various
attributes of each procedure and asked patients to indicate on a Likert scale how important each
attribute was to them, with a suggestion at each end of the spectrum corresponding to the
appropriate treatment option that fit with the value being expressed by the question. For example:

How important is it to you to avoid a stoma/ ileostomy?
Not
Very
important
0

Important
1

You should consider
ileostomy

2

3

4

5

You should consider pouch

Throughout our literature review we did not identify any studies that directly compared
survival between the two surgical options. Although it is not known with certainty, the survival
following each option is likely to be similar given the same control of disease. Thus we have
chosen to focus on highlighting the procedure-specific complications with our decision aid, in an
effort to help patients understand the difference between the two procedures. The prototype aid
can be found in Appendix B.

6.1.3 Input from Surgeons and Enterostomal therapists
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Now that a rough prototype has been developed, we will present it to a group of three
colorectal surgeons and two enterostomal therapists to obtain their feedback on the content,
format, layout, and practical aspects of the prototype. We will also ask them to describe any
information they feel is important to the patient interaction that we have omitted from the aid. The
prototype will then be refined using this feedback. The interview guide for this focus group is
included in Appendix C.

6.1.4 Input from Patients
We will conduct focus groups with patients who have had a proctocolectomy for
ulcerative colitis. The goal of these groups is to identify information helpful to patients deciding
between treatment options. In order to generate as much information as possible, we will use
maximum variation sampling20 by including patients that have had both surgical options, and
patients that did and did not have complications following surgery. We will present the prototype
to two groups, one of patients who underwent ileostomy and one of patients who underwent
restorative proctocolectomy. Similar to our interaction with surgeons, we will seek feedback on
the content, format, layout, and practical aspects of the aid. We will ask patients to describe any
information they feel is relevant to the decision that we have omitted. Based on the information
received from the patients we will modify the prototype further to incorporate their suggestions.
This prototype will then be piloted on three patients who have recently undergone a
proctocolectomy to further refine the aid for clarity and practicality. These patients will be
recruited by their surgeon. The interview guide is included in Appendix D.
6.1.5 Reliability and Validity Testing
Once we have a refined prototype we will evaluate it in healthy volunteers for reliability
and validity according to previously published methodology5, 14, 1521,22. We have decided to use
volunteers rather than patients because it is clinically inappropriate and potentially unethical to
manipulate information concerning therapy and outcomes to patients at the decision point21,22. An
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interviewer will administer the instrument to 30 volunteers who will then state a preference
between the two surgical options. In order to establish reliability we will re-administer the
instrument 2 weeks later to the same volunteers and ask them to state their treatment preferences
again. Reliability between treatment preferences will be measured using a kappa statistic. To
establish validity we will change the information provided in the decision aid and determine if the
volunteers’ treatment choices change in a predictable manner based on the change in information
present on the decision aid. For example, if a volunteer prefers the IPAA treatment option we will
change the information to reflect an increase in pouch failure and see if manipulating the
information present in the aid can result in a predictable change in decision. Volunteers will be
recruited by use of posters put up at both the UWO campus, and in University and Victoria
Hospitals. The datasheet used for this portion of the project is included in Appendix E. University
ethics approval form for this portion of the project is included in Appendix F.

Systematic review and data abstraction

Creation of rough prototype

Presentation of prototype to surgeons and enterostomal therapists

Presentation of refined prototype to two groups of patients (ileostomy group and restorative
proctocolectomy group)

Piloting of Aid to patients who have undergone the decision for clarity

Evaluation of aid for reliability and validity in healthy volunteers
Figure 6.1 Flow Chart Outlining Steps in the Development of the Decision Aid.
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6.2 Conclusions and Further Directions
This work outlines the steps necessary in the design of a decision aid to help
patients with ulcerative colitis decide between ileostomy and IPAA procedures. Although
limited by the poor quality and heterogeneous literature, we used a systematic and
rigorous process of exploring heterogeneity amongst the IPAA studies in order to select
the most appropriate subgroup of studies to include in the aid. With a valid and reliable
decision aid, the next step would be its evaluation on patients with ulcerative colitis. The
aid will be administered to patients with ulcerative colitis who are at the decision point
and following this several established outcomes for decision aids would be assessed
including knowledge about the options and their complications, decisional conflict16, risk
perception12, 17, preferred role in decision making18, and satisfaction with decision
making19. This evaluative process would necessitate a randomized controlled trial and the
specific methodology is beyond the scope of this work, but is the next step in the
evaluation of this decision aid.
There now exist a wealth of literature supporting the benefits of decision aids in
enhancing the decision making process for patients. The decision between an ileostomy
or a restorative pouch procedure is well suited to the use of a decision aid and with a
rough proto-type now designed, further work will look towards refinement and evaluation
of this aid with the hope of improving these patients decision making process.
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APPENDIX A- Search Strategies Used to Identify Primary Studies

Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid
MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present>
Search Strategy:
-------------------------------------------------------------------------------1 exp Colitis/ or Colitis, Ulcerative/ or Inflammatory Bowel Diseases/
2 (inflammatory bowel disease$ or ulcerative colitis or IBD or colitis).mp.
3 1 or 2
4 Colonic Pouches/ or Proctocolectomy, Restorative/ or Ileostomy/
5 (j pouch$ or y pouch$ or w pouch$ or continent pouch$).mp.
6 (ileo pouch anal-anastomosis or ileo pouch anal anastomosis or IPAA or endileostomy or end ileostomy or ostom$ proctocolectom$ colectom$).mp.
7 4 or 5 or 6
8 3 and 7
9 limit 8 to yr="1978 -Current"
***************************

Database: Cochrane Library
Search Strategy:
-------------------------------------------------------------------------------1 ((ulcerative adj2 coliti$) or coliti$ or (inflammatory bowel adj2 disease$) or IBD or
inflammatory bowel).mp.
2 (ileo pouch anal anastomosis or ileonalanastomosis or IPAA or anastomosis).mp.
3 (proctocolectom$ or end-ileostom$ or end ileostom$ or ileostom$ or ostomy).mp.
4 (colonic pouch$ or continent pouch$ or y pouch or w pouch or j pouch or ileoanal
reservoir$ or anal reservoir$).mp.
5 2 or 3 or 4
6 1 and 5
7 limit 6 to yr="1978 -Current"
***************************
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Database: Embase
Search Strategy:
-------------------------------------------------------------------------------1 exp Colitis/ or Enteritis/ or Ulcerative Colitis/
2 (inflammatory bowel disease$ or ulcerative colitis or IBD or colitis).mp. (77269)
3 1 or 2
4 ileoanal anastomosis/ or ileostomy/ or proctocolectomy/ or continent ileostomy/ or
Colon Pouch/
5 colon pouch/ or rectum anastomosis/ or exp rectum resection/
6 (colon$ pouch$ or ileoanal anastomosis or proctocolectom$ or ileostom$ or colon
pouch$ or ostomy).mp.
7 (j pouch$ or y pouch$ or w pouch$ or continent pouch$).mp.
8 4 or 5 or 6 or 7
9 3 and 8
10 limit 9 to yr="1978 -Current"
11 remove duplicates from 10
***************************
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APPENDIX B-PROTOTYPE DECISION AID
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APPENDIX C-Prototype-Refinement Phase I
Interview Guide
Group: Surgeons and Enterostomal Therapists
Moderator: Luc Dubois
Method: Focus Group
Goals:
1) Collect input from surgeons and enterostomal therapists on the
content, format, and practical aspects of the decision aid.
2) Seek additional information surgeons or eneterostomal therapists
find relevant to the decision.
Pre-amble
“ I would like to thank everyone for agreeing to help with this research project. The goal
of this project is to develop a decision aid that will help patients with ulcerative colitis
choose between restorative proctocolectomy with ileal anal-pouch anastomosis or endileostomy. The purpose of this meeting is to discuss and comment on the decision aid we
have constructed. We are seeking your input into the content, format, and practical
aspects of the decision aid.
This discussion should take approximately one hour. We will record this discussion and
analyse the recording to identify any recommendations and refinements for the decision
aid.
Your answers will be kept confidential and your participation in this group is voluntary,
you may leave or refuse to participate at any time.
Before we begin are there any questions about this project or the purpose of this meeting?
”

I Present the decision aid prototype to the group
II Seek input from surgeons and enterostomal therapists on the
following domains:
1) Content
Framing question:
Do you have any comments on the content we have included in the aid?
Follow-up questions:
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Do you think the information about the procedure, benefits, functional outcomes, and
risks accurate?
Would you be comfortable presenting this information to your patients?

Is there any further information you would recommend we include in the aid that we have
not presented?
Is the language of an appropriate level for your patients?
Should we include graphical representations or pictures of certain aspects of the
procedure?

Is there any information you don’t understand or think patients would have difficulty
understanding?
Are there any changes you would make to the content of the aid?
2) Format
Framing question:
Do you have any comments about the format of the aid?
Follow-up questions:
Do you think the current format facilitates discussion with patients?
Are there any other formats (board, pamphlet) that you would prefer for the aid?
Are there any changes you would make to the format?
3) Practical Aspects
Framing question:
Do you have any concerns about the practical aspects of the aid?
Follow-up questions:
In your opinion, how long should the aid take to administer?
Are there any elements of the aid you think would hamper patient interaction?
Are there any elements that we have omitted that would aid patient interaction?
Are there any changes you would make to the aid to improve its practicality?
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4) Overall Impression:
Know that you have considered all aspects of the aid, are there any further changes you
would recommend we make?

III Closing Remarks
“Are there any remaining questions or comments? The audio recording will be analyzed
and the aid will be modified according to your feedback. A modified version of the aid
will be sent to you once the changes are made. Thank you again for participating in our
research project.”
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Prototype-Refinement Phase I
Data Sheet Group: Surgeons and Enterostomal Therapists
Date of focus group:
Participant Characteristics
Surgeon
1
2
3

Age

Sex

Years in Practice

Enterostomal
Therapists
1
2
3

Age

Sex

Years in Practice

Results of Group Discussion

Comments

Changes Proposed
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APPENDIX D Prototype-Refinement Phase II
Interview Guide
Group: Patients with ileal anal-pouch anastomosis
Moderator: Luc Dubois
Method: Focus Group
Goals:
1) Collect input from patients on the content, format, and practical
aspects of the decision aid.
2) Seek additional information patients find relevant to the decision.
I Pre-amble
“ I would like to thank everyone for agreeing to help with this research project. The goal
of this project is to develop a decision aid to assist patients with ulcerative colitis when
deciding between two surgical options. One is to remove the colon and make a new
rectum from the small bowel (ileal anal-pouch anastomosis), the other is to bring the
small bowel out to the skin as an ileostomy. The purpose of this meeting is to discuss and
comment on the decision aid we have constructed. We are seeking your input into the
content, format, and practical aspects of the decision aid.”
“This discussion should take approximately one hour. We will record this discussion and
analyse the recording to identify any recommendations and refinements for the decision
aid.”
“Your answers will be kept confidential and your participation in this group is voluntary,
you may leave or refuse to participate at any time.”
“We recognize that discussing aspects of your prior treatment and illness may be
upsetting, if you feel you need to leave at any moment, please feel free to do so. If you
feel you require any counselling or other help following this meeting, we will work with
you to arrange it.”
“Keep in mind that there are no right or wrong answers to these questions.”
“Before we begin are there any questions about this project or the purpose of this
meeting? ”

II Present the decision aid prototype to the group
III Seek input from patients on the following domains:
1) Content
Framing question:
Do you have any comments on the content we have included in the aid?
Follow-up questions:
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Is the information we have presented in the aid easy to understand?
Would the information in the aid be helpful in making a treatment decision?
Is there any information you think we should add to the decision aid?
Are there any elements of the decision aid we need to clarify?
Would the use of pictures representing the procedures help?
Do you think there is too much information included in the aid?
Do you think there is too little information in the aid?
Is there any language used in the aid that you feel is threatening?

2) Format
Framing question:
Do you have any comments about the format of the aid?
Follow-up questions:
Do you think the current format facilitates discussion with a surgeon?
Are there any other formats (board, pamphlet) that you would prefer for the aid?
Are there any changes you would make to the format?
Do you think a take-home version of the aid would be beneficial?
3) Practical Aspects
Framing question:
Do you have any concerns about the practical aspects of the aid?
Follow-up questions:
In your opinion, how long do you think it should take you to go through the aid?
Do you think any parts of the aid will prevent discussion with the surgeon?
Is the current layout easy to use?
Is the current layout inviting?
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Would you recommend any changes to the layout or any other aspects of the aid?
4) Overall Impression:
Know that you have considered all aspects of the aid, are there any further changes you
would recommend we make?

IV Closing Remarks
“Are there any remaining questions or comments? The audio recording will be analyzed
and the aid will be modified according to your feedback. Thank you again for
participating in our research project. If you have any residual questions please feel free to
contact me.”

207

Prototype-Refinement Phase II
Data Sheet
Group: Patients with ileal anal-pouch anastomosis
Date of focus group:
Participant Characteristics
Patients

Age

Sex

Years Since
Surgery

1
2
3
4
5
6
7
8

Results of Group Discussion

Comments

Changes Proposed
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Appendix E- Reliability and Validity Testing
Data Sheet-Page 1
Participant Number
___ ___
Date: __ __ __ __-__ __-__ __
Demographic Information
1.Age (years)

_____________

2.Gender

□ Male

3.Relationship
Status

□ Married/ Cohabitating
□ Single/ divorced/ widowed

4.Education

□ High School or equivalent or less
□ College or University (post-secondary)

□ Female

Decision Information: First Encounter
Time of administration (mins)

_____________

Decision with normal probabilities

□ End-ileostomy
□ Ileal anal-pouch anastomosis

Decision with altered probabilities
(validity)

□ End-ileostomy
□ Ileal anal-pouch anastomosis

How easy was it to understand the
information presented in the aid?

□ Very Easy
□ Somewhat Easy
□ Somewhat Difficult
□ Very Difficult

How helpful was the decision aid
in assisting you when making the
decision?

□ Very Helpful
□ Somewhat Helpful
□ Somewhat Unhelpful
□ Very Unhelpful

Decision Information: Second Encounter (reliability)
Date of Second Encounter

__ __ __ __-__ __-__ __

Decision with repeated
administration

□ End-ileostomy
□ Ileal anal-pouch anastomosis
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2. Ahmadi N, Dubois L, McKenzie , Brown CJ, MacLean A, McLeod RS. Role of
evidence based reviews in surgery in teaching critical appraisal skills and journal
clubs. Submitted: Canadian Journal of Surgery, Feb 2012.
3. Vogt KN, Dubois L, Etemad-Rezi R, Schlachta CM. Diagnostic yield of imaging
for patients presenting with suspected acute appendicitis. Submitted: Journal of
the American College of Surgeons Jan 2012.
4. Vogt KN, Dubois L, Merritt N. Use of focused assessment with sonography for
trauma (FAST) in North American pediatric trauma centres. Submitted: J Trauma,
Nov 2011

Abstracts Presented (Presenter underlined):
1. Vogt KN, Dubois L, Vinden C. “Specialty bias” may help explain variable results
of CT colonography in the literature. Poster at the ASCRS Annual Scientific
Meeting Vancouver BC May 2011.
2. Vogt KN, Van Koughnett JA, Dubois L, Gray DK, Parry N. The use of trauma
transfusion pathways for blood component transfusion in the civilian population:
A systematic review and meta-analysis. Presented at the ACS Region XII Resident
Research Competition Quebec City QC September 2010 (Winner); Poster at the
Trauma Association of Canada Annual Scientific Meeting Banff AB April 2011
(Winner).
3. Dubois L, Vogt KM, Davies W, Schlachta CM. Impact of and outpatient
appendectomy protocol on clinical outcomes and cost: A case-control study. The
Canadian Surgical Forum, Victoria, BC, 2009
4. Dubois L, Leslie K, Parry N. FACTS Survey: FAST use Among Canadian
residents Training in general Surgery. The Canadian Surgical Forum: TAC/ACS
Canadian Resident Papers
Competition, Victoria, BC, 2009.

5. Racz JM, Dubois L, Katchy A, Wall WJ. Elective and emergency abdominal
surgery in patients 90 years of age or older- clinical outcomes and the evaluation
of the POSSUM and P-POSSUM scoring systems as predictors of mortality. The
Canadian Surgical Forum, Victoria, BC, 2009.
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6. Vogt KN, Dubois L, Hobbs A, Etemad-Rezai, Schlachta CM. Diagnostic yield of
imaging for patients presenting with suspected acute appendicitis. The Canadian
Surgical Forum, Victoria, BC, 2009.
7. Dubois L, Karanicolas PJ, Colquhoun PHD, Guyatt GH. Short-term outcomes
following colorectal resection for diverticular disease in Canada. The Canadian
Surgical Forum, Halifax, NS, 2008.
8. Karanicolas PJ, Colquhoun PHD, Dubois L, Swallow CJ, Guyatt GH. An analysis
of 1486 colorectal resections performed for inflammatory bowel disease in
Canada. The Canadian Surgical Forum, Halifax, NS, 2008.
9.

Dubois L, Malthaner RA. VATS apical bulectomy and talc poudrage in the
treatment of spontaneous pneumothoraces: effect on pulmonary function and 1year results.18th World Congress-World Society of Cardio-Thoracic Surgeons,
Kos Island, Greece, 2008.

10.

Dubois L, Gray DK. Predictors of response to splenectomy in patients with
immune thrombocytopenic purpura. Resident Research Retreat, The Canadian
Surgical Forum, Calgary, Alberta, 2006.

11. Campbell DA, MacDonald TM, Dubois LA, Comeau S, Smith S. Moderate
UVB triggers dynamic regulation of cpc, psbA, rbcL transcripts in the
cyanobacterium Synechococcus sp, PCC 7942. 12th International Photosynthesis
Congress, Brisbane, Australia, 2001.
12. MacKenzie, TD, MacDonald TM, Dubois LA, Campbell DA., Seasonal changes
in temperature and light drive acclimation in a lichen. 12th International
Photosynthesis Congress Brisbane, Australia, 2001.

Research Grants:
1. Physician Services Incorporated Foundation Resident Research Grant, PSI
Foundation. (August 2010). Project Title: The use of gentamicin-impregnated
collaged implants to prevent surgical site infection in colorectal surgery. A
randomized controlled trial. Principle Investigator: KN Vogt; Co-investigator and
trial statistician: L Dubois. ($20 000)
Awards and Distinctions:
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1. Department of Surgery Research Award for Best Resident Paper (Western):
For the paper entitled, Technical Factors are Strongest Predictors of Postoperative
Renal Dysfunction Following Open Juxtarenal Aneurysm Repair, 2012
2. G. E. Meads Award: For Excellence in technical ability and teaching in general
surgery residency, 2011.
3. Stevens Norvell Award: for the highest mark amongst all Canadian residents in
general surgery on the annual Canadian Association of General Surgeons exam,
2011.
4. Stevens Norvell Award: for the second highest mark of all Canadian PGY-4
residents in general surgery on the annual Canadian Association of General
Surgeons exam, 2010.
5. Canadian Association of General Surgeons: Resident Award for Teaching
Excellence. June 2010.
6. Best Research Poster Award: Impact of and outpatient appendectomy protocol on
clinical outcomes and cost: A case-control study. The Canadian Surgical Forum,
2009.
7. Best Resident Research Paper from Ontario: FACTS Survey: FAST use Among
Canadian residents Training in general Surgery. TAC/ACS Canadian Resident
Papers, The Canadian Surgical Forum, 2009.
8. Stevens Norvell Award: for the highest mark of all Canadian PGY-3 residents in
general surgery on the annual Canadian Association of General Surgeons exam,
2008.
9. Schulich Graduate Scholarship for Medical Research, 2007&2008.
10. Patterson Scholarship for Clinical Investigators Program, 2008.
11. Stevens Norvell Award: for the second highest mark of all Canadian PGY-1
residents in general surgery on the annual Canadian Association of General
Surgeons exam, 2006.
12. Best First Year Research Paper: Predictors of response to splenectomy in patients
with immune thrombocytopenic purpura. UWO General Surgery Annual Resident
Research Day, 2006.
13. Dr. Fred N. Hagerman Memorial Prize in Surgery: awarded to the graduating
student in medicine showing the greatest merit in surgery, 2005.
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14. Kingswood Scholarship: awarded to the graduating student in medicine considered
the most proficient by the authorities of the university, 2005.
15. Dr. C.C. Ross Memorial Prize in Surgery: awarded to the student at the end of
clinical clerkship showing the most proficiency in surgery, 2004.
16. John C. Rathbun Memorial Prize in Pediatrics: awarded to the student who
receives the highest evaluation at the completion of the clinical clerkship in
pediatrics, 2004.
17. Rachel Slobasky Kaplan Scholarship: awarded annually to the student achieving
the highest standing in the examinations at the conclusion of year two of medicine,
2003.
18. J.A.F. Stevenson Award: awarded annually to one medical student from any year
on the basis of academic excellence in the previous year, 2003.
19. Meds Class of 1940 Scholarship in Medical Sciences: awarded to the student
entering year three of medicine based on the highest cumulative score of all science
courses taken during year one and two of medicine, 2003.
20. American Society for Clinical Pathology Award for Academic Excellence and
Achievement: awarded to one student per medical school in Canada for academic
excellence in the field of pathology, 2003.
21. Marvin L Kwitko Scholarship in Anatomy: awarded to the student in year one of
medicine with the highest standing in anatomy, 2002.
22. Rix Family Award in Pathology: awarded to the student in year one of medicine
with the highest standing in pathology, 2002.
23. J.B. Campbell Memorial Scholarship in Physiology: awarded to the student in
year one of medicine with the highest standing in physiology, 2002.

Academic Activities:
Committee Membership:
1. Evidence Based Reviews in Surgery Steering Committee, 2008-2009.
2. Ontario Association of General Surgeons, program representative, 2009-2011.
3. Chair, Resident Committee, Canadian Association of General Surgeons, 20062008.
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4. Post-Graduate Education Committee, Canadian Association of General Surgeons,
2006-2008.
5. Canadian Surgical Forum Planning Committee, Canadian Association of General
Surgeons, 2006-2008.
6. Residency Training Committee, Division of General Surgery, University of
Western Ontario, 2006-2008.
7. Resident Selection Committee, Division of General Surgery, University of
Western Ontario, 2006-2009.
Administrative Positions:
1. Chief Vascular Surgery Fellow, Victoria Hospital, July 2011 - June 2012.
2. Chief General Surgery Resident, Victoria Hospital, January – April 2011.
3. Chief General Surgery Resident, University Hospital, January – June 2010.
Courses Attended:
1. SAGES Laparoscopic Colorectal Surgery Course, London, Ontario, February
2010.
2. Principles and Practice of Clinical Research for Surgeons, Mississauga, Ontario,
November 2008.

Professional Memberships & Development:
Professional Memberships
1. International Society for Vascular Surgery , member 2012-present
2. Canadian Association of General Surgeons, resident member, 2005-2011.
3. American College of Surgeons, resident member, 2006-present.
Professional Development
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1. Fellow Royal College of Surgeons Canada, General Surgery, June 2011.
2. SAGES Fundamentals of Laparoscopic Surgery Program, London, Ontario, July
2009.
3. Principles of Surgery Exam, the Royal College of Physicians and Surgeons, April
2007.
4. Qualifying Examination Part II, Medical Council of Canada, October 2006.
5. ATLS Provider Course, July 2005.
6. ACLS Provider Course, April 2005.
7. Qualifying Examination Part I, Medical Council of Canada, April 2005.

